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Abstract 
 
Resource Guide for Speech-Language Practitioners: Side Effects of 
Seizure Medications 
 
Jennifer Le Ho, M.A.  
The University of Texas at Austin, 2014 
 
Supervisor:  Barbara L. Davis 
 
Side effects of seizure medications in individuals with intellectual disabilities (ID) 
may affect speech and language development for this population. Research information 
about these effects may be useful for speech-language pathologist practitioners, since 
they will most likely work in environments that involve assessing and treating individuals 
with ID.  In this meta-analysis, a total of 19 articles were reviewed to examine the side 
effects of AEDs in individuals with ID and seizure disorders. Side effects from AEDs 
were found; however, research regarding how AEDs and seizure disorders affected 
speech and language development was not available. Based on the findings, participants 
on AEDs regimens experienced a variety of side effects that included behavioral side 
effects, adverse cognitive side effects, and non-behavioral side effects.  However, 
information regarding AEDs side effects and speech and language development was 
nonexistent. Based on the findings, further research in this is much needed for practicing 
speech-language pathologists in this topic.  
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INTRODUCTION 
Side effects of seizure medications in individuals with intellectual disabilities (ID) 
may affect speech and language development for this population. Research information 
about these effects may be useful for speech-language pathologist practitioners, since 
they will most likely work in environments that involve assessing and treating individuals 
with ID. For this review, individuals with ID were selected because this population has a 
higher prevalence of seizure disorders (Richardson et al. 1979; Corbett 1993; Wilcox and 
Kerr 1996). The rationale for examining the side effects of seizure medications was due 
the higher prevalence of seizures in children with communication disorders in 
comparison to the general population (Stephenson 1999). Since speech-language 
pathologist practitioners may not have extensive pharmacological knowledge about 
seizure medications and their side effects, this review may provide resourceful 
information. The goals of this review were to examine what types of side effects were 
reported with various seizure medications and how seizure medication side effects may 
impact speech-language pathologist practitioners in assessing and treating individuals 
with ID. 
As a background to considering medications effects for seizure disorders, it is 
important to understand the prevalence of seizure disorders in the United States, 
especially in individuals with ID.  More than 2 million individuals in the United States 
are affected by seizure disorders, and individuals with intellectual disabilities (ID) are 
more likely to suffer from seizures disorders in contrast to the general population 
(Matson 2004; Wilfong 2002; Shannon 2010). Relative to the general population, 
individuals with ID are 26 percent more likely to have a seizure disorder (McGrother et 
al. 2006). According to Singh and White-Scott (2002), seizure disorders are a 
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concomitant neurological disorder in 40 to 50 percent of individuals with ID and 
developmental disabilities.   
Various options for treating seizure disorders are presently available. One of the 
most common ways of managing seizure control is through medication regimens. These 
medications used to treat seizures are called anticonvulsant or antiepileptic drugs (AEDs). 
AEDs are frequently used to treat seizure disorders, but can yield significant side effects, 
especially in individuals with ID (Meador et al. 2001).  Significant side effects of AEDs 
include behavioral or non-behavioral outcomes. Some behavioral side effects from 
anticonvulsants from anticonvulsants include aggression, hyperactivity, and irritability 
(Harbord 1999). Non-behavioral side effects from anticonvulsants have included rash, 
headache, gastrointestinal disturbance or drowsiness, or increase seizures (Harbord 
1999). These significant side effects could affect individuals with ID relative to their 
ability to maintain social interactions as well as cognitive functioning. Cognitive function 
side effects from AEDs that have been described include difficulties with attention and 
memory (Motamedi & Meador 2003).  
Because of the proposed effects on social interactions and cognitive function, it is 
important to examine effects of medications on speech and language acquisition. In this 
way, clinicians can better prepare for planning speech and language interventions in 
individuals with ID. Since seizure disorders require treatment throughout a person’s 
lifetime, it is important to include children and adults who suffer from seizures with ID in 
this review. Having a better understanding of the possible side effects of AEDs will allow 
clinicians to better work with the client and their families most productively. Research for 
this topic is limited. In addition, the American Speech Language and Hearing Association 
(ASHA) does not yet provide specific guidelines for working with individuals who may 
experience medication side effects. Improving clinician understanding will ultimately 
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benefit both clients and their families while improving treatment for children and adults 
who may receive seizure medications on an ongoing basis.   
 
Background and Terminology 
For the purpose of this literature review, background and terminology will be 
discussed. Some of the research employs some different terminologies. In addition, much 
of the literature reviewed in this report employs terminologies that have changed over the 
years. 
    
EPILEPSY 
Epilepsy is defined as a neurological disorder that is caused by the abnormal or 
excessive neuronal activity within the brain (Shannon 2011). Abnormal disturbance in 
neuronal activity within the brain are termed seizures. Seizures can result in the loss of 
consciousness, involuntary movement, or convulsions (Haggerty 2002). The number of 
seizures an individual may experience may vary. Some individuals may experience 
seizures occasionally, while others may experience seizures multiple times per day 
(Shannon 2011). While individuals who have seizures may not have epilepsy, a person 
with more than two seizures is considered to have a seizure disorder called epilepsy 
(Shannon 2011).   
Epilepsy is the second most common neurological disorder (Judd 2012). Each 
year, approximately 200,000 individuals are diagnosed with epilepsy; of that population, 
approximately 45,000 individuals are children and adolescents (Judd 2012). The highest 
incidence of epilepsy occurs in children under the age of 10 years and adults above the 
age 70 years (Judd 2012). It has been reported that African Americans and socially 
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disadvantaged populations have a higher prevalence of epilepsy; however, seizure 
disorders affect all nations and ethnicities (Judd 2012). Since there are no known cures 
for epilepsy to date, medication and surgical techniques are often used to manage or 
control seizures (Shannon 2011).  
CAUSES OF EPILEPSY  
There are many possible causes of epilepsy, since it may be caused by any factor 
that disrupts the normal pattern of neuronal activity (Shannon 2011). An abnormal 
imbalance of neurotransmitters may cause individuals to experience seizures (Shannon 
2011). Some factors that may cause seizures that have been discussed include illnesses, 
abnormal brain development due to genetic factors, stroke, or trauma to the brain. It is 
important to understand the causes of seizures or factors that may cause seizures, since 
there has been reported stigma suggesting epilepsy is contagious (Shannon 2011). 
Although these are possible causes of seizures, it is important to keep in mind that about 
half of all seizure disorders have no known cause. 
About 40 percent of seizures are attributed to genetic factors that result in 
epilepsy (Letcher 2005). Gene mutations can cause abnormal nervous system 
development that may cause epilepsy (Letcher 2005). The majority of generalized 
epilepsy disorders and some partial epilepsy disorders have genetic components 
associated with the cause of epilepsy (Letcher 2005).  
Next, it is important understand some of the most common types of seizures that 
affect individuals with epilepsy disorders. If the cause of the seizures is known, a better 
understanding of what deficits may arise if the seizures occur in a specific location in the 
brain is possible.   
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TYPES OF SEIZURES  
Many different types of seizures have been described by physicians (Shannon 
2011). Seizures can be divided into two major categories: focal seizures and generalized 
seizures. Focal seizures are also known as partial seizures, which mean these seizures 
presents itself in a specific location in the brain (Shannon 2011).  
Focal seizures are divided into two categories called complex partial seizures and 
simple focal seizures (Shannon 2011). In complex partial seizures, individuals typically 
experience change or loss of consciousness, where an individual may experience a 
dream-like state (Shannon 2011). An individual with a complex partial seizure may be 
characterized by having repetitive behavior that may occur involuntarily (Shannon 2011).   
Repetitive behaviors may include blinks, mouth movements, twitches, or continue 
activities before seizures occur (Shannon 2011). Complex partial seizures are 
characterized by loss of consciousness. In contrast, individuals with simple complex 
seizures will remain conscious but the seizure is accompanied with atypical sensations 
(Shannon 2011). Individuals with simple partial complex seizures may experience 
changes in moods, such as happiness, anger, or nausea (Shannon 2011).  The majority of 
people with epilepsy usually have focal seizures, such as temporal lobe seizures that may 
cause the hippocampus to shrink overtime (Shannon 2011). Shrinking of the 
hippocampus over time that may cause impairments in learning and memory (Shannon 
2011).  
Individuals with generalized seizures usually experience abnormal neuronal 
activity on both hemispheres of the brain (Shannon 2011). Generalized seizures may 
cause individuals to experience loss of consciousness, falls, or severe muscle spasms 
(Shannon 2011). Since there are many different types of generalized seizures, some 
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examples of generalized seizures include tonic seizures, clonic seizures, and clonic-tonic 
seizures (Shannon 2011).  
For this review, only a few major categories have been discussed since some 
seizure disorders do not have a specific pattern to categorize them. It is important to keep 
in mind that these types of seizures are not the only types.   
TREATMENT OF EPILEPSY 
Treatment of epilepsy typically consists of medical and surgical techniques for 
approximately 70 percent of individuals (Shannon 2011). Although the majority of 
individuals with epilepsy may be treated with medication or surgical techniques, not all 
individuals benefit from such treatments (Shannon 2011). Use of antiepileptic drugs 
(AEDs) is the most common treatment for controlling epilepsy (Shannon 2011).  
There are many different AEDs drugs available to treat epilepsy that yield 
different benefits and side effects. In order to find the right prescription medication for 
individuals with epilepsy, factors such as type of seizures, personal lifestyle, age, and 
frequency of seizures play a critical role (Shannon 2011).  
AEDs are categorized as new AEDs and old AEDs. Newer AEDs consist of 
carbamazepine, valproate, lamotrigine, oxcarbazepine, or phenytoin (Shannon 2011). 
AEDs, such as ethosuximide are mostly used for individuals with absence seizures. Other 
medications that are also commonly prescribed include clonazepam, phenobarbital, and 
primidone. Newer AEDs include tiagabine, gabapentin, topiramate, levetiracetam, and 
felbamate. For intractable seizures, these drugs may be used in combination with other 
drugs if seizures are not responsive to the medication. For the majority of individuals 
with epilepsy, seizures can be managed with one AED, but for those who use multiple 
drugs have an increased incidence of side effects (Shannon 2011). Types of medications 
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are available for seizure control and more information about AEDs will be provided later 
in the report.  
When an individual with epilepsy does not respond to treatment with medication, 
these individuals are further evaluated in order to see if they are candidates for surgery. 
Before these individuals are considered for surgery, many factors are taken into 
consideration. Factors include the location of the seizure and how this location affects an 
individual’s daily living activities. Although surgery may significantly reduce the 
frequency of seizures, surgery used to treat epilepsy may not work at all (Shannon 2011).   
This general information about surgical techniques for epilepsy may be important 
for clinicians in terms of thinking about which functions of the brain may be impaired 
after surgery. Thinking about impairments relative to the parts of the brain removed may 
help clinicians be more knowledgeable when working with their clients and their families 
by providing appropriate support and treatment plans relative to the area of neural 
differences.   
INTELLECTUAL DISABILITY  
Since this review focused on individuals with ID, it is important to define ID and 
how it relates to seizure disorders. Side effects of medication may be more pronounced in 
this population. Many articles refer to individuals with ID as ‘mentally retarded’, or 
‘cognitively impaired’. For this review, the term intellectual disabilities or individuals 
with ID are used.  
A few types of epilepsy are treated with surgery when medications are ineffective. 
Removal of a seizure focus is one of the most common surgical procedures. A small part 
of an area of the brain is removed (Shannon 2001). Physicians may refer to this type of 
procedure as a lobectomy or lesionectomy (Shannon 2011). When doctors cannot remove 
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a section of the brain where seizures originate, they may use a procedure called multiple 
subpial transection (Shannon 2011). In order to prevent seizures from spreading into 
other parts of the brain, surgeons make a series of cuts around sections of the brain 
(Shannon 2011).  
Corpus callosotomy is a surgical procedure performed by surgeons by severing 
the neural connections between the hemispheres of the brain (Shannon 2011). This 
procedure is usually performed on children who have severe seizures that spread from 
one side of the brain to the other (Shannon 2011). When seizures that occur on one side 
of the brain and does not respond to medication treatment, children with seizures may 
have a hemispherectomy and hemispherotomy (Shannon 2011). Surgeons consider these 
procedures as very extreme since the procedures involve removing half of the cortex of 
the brain (Shannon 2011).  
According to Ferrara (2010), individuals with ID are characterized as having 
impairments or delays in cognitive, social, practical, and abstract learning skills, which 
may cause difficulties with communication, health and safety, and school performance. 
Intellectual disabilities are usually categorized through cognitive assessments. These 
cognitive assessments can classify individuals with ID in four categories: mild, moderate, 
severe, and profound levels of disability.  
Individuals with mild disability have an intelligence quotient (IQ) range of 52 to 
69 (Ferrara 2010). These individuals make up about 75 to 90 percent of all cases of ID 
(Ferrara 2010). Children with mild disabilities have delays in learning to walk, talk, and 
to feed themselves than other typically developing children (Ferro 2010). Many children 
with mild disabilities may go undiagnosed until later in their school years (Ferrara 2010).  
As children with mild disabilities mature, they may acquire practical, social, and job 
skills (Ferro 2010).  
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Individuals with moderate disabilities have an IQ range of 36 to 51 (Ferro 2010). 
This population makes up about 10 to 25 percent of all cases of ID (Ferro 2010). Children 
with moderate disability have apparent delays in speech development and motor (Ferro 
2010). These individuals will most likely not acquire academic skills, but may learn some 
basic communication skills (Ferro 2010). Adults with moderate disability may acquire 
skills for completing simple tasks and potentially travel independently in familiar places 
(Ferro 2010). These individuals usually require supervision and may not live 
independently (Ferro 2010).  
Individuals with severe disability have an IQ range of 20 to 35 (Ferro 2010). 
These individuals make up 10 to 25 percent of all cases of ID (Ferro 2010). Children with 
severe disability have difficulties in speech, language, and motor development (Ferro 
2010). However, these individuals may acquire some self-help skills and basic 
communication skills, and learn to walk with assistance (Ferro 2010). Adults with severe 
disability may learn to follow daily routines in a safe environment, but require 
supervision (Ferro 2010).   
Individuals with profound disability have an IQ range of less than 20 are usually 
diagnosed shortly after birth (Ferro 2010). Children with profound disability typically 
have other medical issues that need additional monitoring and nursing care (Ferro 2010). 
These individuals have developmental delays in all areas of development (Ferro 2010). 
With intensive therapy, children with profound disability may learn how to use their legs, 
hands, and jaws (Ferro 2010). In adulthood, these individuals may acquire some speech 
and may learn to walk (Ferro 2010). These individuals require full support and 
supervision in their daily living (Ferro 2010).  
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CAUSES OF INTELLECTUAL DISABILITIES 
Intellectual disabilities may be caused by genetic factors, such as chromosomal 
abnormalities (Ferrara 2010). Although genetic factors may play a role in ID, other 
factors that may cause ID may occur from complications during pregnancy or childbirth 
(Ferro 2010). Complications from pregnancy or childbirth may result in damage to the 
fetal brain and central nervous system (Ferrara 2010). ID may also result from lack of 
proper nutrition or poor nutrition and medical care during pregnancy (Ferrara 2010).  
RELATIONSHIP BETWEEN ID AND SEIZURE MEDICATION 
In the introduction, it was noted that individuals with ID were more likely to have 
seizure disorders compared to the general population in the United States. Many 
individuals with ID use AEDs to manage and control seizures. However, various AEDs 
may yield undesirable side effects. According Harbord (2002), these findings revealed 
that children with ID have a three times greater chance to experience a behavioral side 
effect from AEDs in comparison to children without ID. Researchers are not sure why 
children with ID are more likely to experience behavioral side effects from AEDs, but it 
is important for clinicians to be aware of when medications are changed. 
SERVICES FOR INDIVIDUALS WITH SEIZURES 
Since many speech-language pathologist practitioners work in school settings, 
information about qualifying services for children in school may be a useful guide for 
when assessing children to see if they are eligible for services.  
Individuals with epilepsy may experience cognitive side effects that may 
influence their level of functions in their learning or work environment (Judd 2012). 
Cognitive side effects from seizures are not an uncommon occurrence for individuals 
with epilepsy. Since epilepsy may affect a child’s learning ability and subsequent 
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development, it may cause children to miss important instruction in the classroom (Judd 
2012). Therefore, it is important for parents, caregivers, and clinicians to be aware of 
what resources are available for their children (Judd 2012). 
Many of the resources available for children with epilepsy are mandated under the 
nation’s special education law known as the Individuals with Disabilities Education Act 
(IDEA) (Judd 2012). IDEA is broken down into two types of services: early intervention 
and special education and related services.  Early intervention is a system that is 
designed to provide services for infants, below the age of three, and their families. For 
older children, the special education and related services provide assistance through 
public schools for preschoolers and school-aged children. This service is for children 
from the age of 3 to 21 (Judd 2012). In order for children to become eligible for these 
services, each child must complete a comprehensive and individual evaluation to 
determine whether a child has a disability, to have more information on how the 
disability affects the child’s abilities in developmentally and academically, and to provide 
documentation of how the child’s disability relates to providing special accommodations 
(Judd 2012).  
For children with epilepsy, services are usually provided under a sub-section of 
the IDEA called Other Health Impairment (OHI). Under the OHI, these impairments 
mean that the child has a limitation on strength, vitality, or alertness, relative to his 
educational environment (Judd 2012) To provide services for these impairments, 
individuals must have an acute or chronic illness such as asthma, attention deficit 
hyperactivity disorder or attention deficit disorder, and epilepsy. Many other illnesses 
may be included are not limited to the ones above (Judd 2012).  As long as the child’s 
illness negatively affects their educational performance, they may be eligible to receive 
services (Judd 2012).  
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If a child is eligible for services within the classroom, accommodations may be 
offered to the individual (Judd 2012).  The Individualized Education Plan team typically 
plans special accommodations for individuals who are eligible for services (Judd 2012). 
Special accommodations are usually provided in the classroom that include providing 
instruction in different formats such as pictures, or by addressing health concerns through 
flexibility in regards to school absence in case of adjusting to new medications or 
treatments (Judd 2012). For those individuals who have seizures, a private area may be 
provided for seizure recovery or rest (Judd 2012).  
 
Anticonvulsants/Antiepileptic Medication  
AEDS FOR VARIED TYPES OF SEIZURES  
Anticonvulsants or antiepileptic medications are designed to control seizures. 
They represent one of the most common treatments for individuals with seizure disorders. 
It is important to know that anticonvulsant medications are not limited in treating 
seizures, but are also used to treat mood disorders as well (Andrews 2010). To have a 
better understanding of AEDs and seizures, types of AEDs used for diverse types of 
seizures will be reviewed. Table 1 below lists older generation AEDs and their uses.  
Older generation AEDs include: phenobarbital, phenytoin, valproic acid, ethosuximide, 
clonazepam, and carbamazepine. These medications are referred as older generation 
AEDs because there were no new AEDs approved from 1978 to 1993 (Hung & Shih 
2011). Carbamazepine is used to treat partial and generalized tonic-clonic seizures (Hung 
& Shih 2011). It has a similar chemical structure to tricyclic antidepressants and has a 
similar mechanism of action as Phenytoin (Hung & Shih 2011). Side effects from 
carbamazepine include diplopia, headache, dizziness, and nausea (Hung & Shih 2011). 
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Clonazepam is used to treat absence seizures, myoclonic jerks, and tonic-clonic seizures. 
Since Clonazepam causes excessive sedation and possible tolerance of the drug, this drug 
has limited use (Hung & Shih 2011).  
Ethosuximide is typically used as a first-line AED for patients with generalized 
absence seizures (Hung and Shih 2011). Side effects from ethosuximide include: 
headache, vomiting, nausea, abdominal pain, sedation, and headache. Phenobartbital is 
used to treat partial and generalized tonic-clonic seizures (Hung & Shih 2011). 
Phenobarbital is as effective in preventing seizures as carbamazepine and phenytoin, but 
is usually prescribed as second-line AED because of the significant cognitive side effects 
(Hung and Shih 2011). Reported side effects of phenobarbital include hyperactivity and 
aggression in children, and excessive fatigue in adults (Hung & Shih 2011). It is also 
important to note that phenobarbital interacts with other medications by causing a 
significant increase of metabolism rate in other AEDs (Hung & Shih 2011).  
Phenytoin is also used to treat partial and tonic-clonic seizures. Common side 
effects of phenytoin are gingival hyperplasia, hirsutism, acne, and facial coarsening 
(Hung & Shih 2011). If the concentration of phenytoin is greater than 20 milligrams, 
other cognitive symptoms may include: ataxia, dysarthria, and lethargy (Hung & Shih 
2011). Phenytoin is usually uses as a first-line AED in emergencies (Hung & Shih 2011). 
Valproic acid is one of the older AEDs that may be used for treating all types of seizure 
disorders (Hung & Shih 2011). This AED may be prescribed for absence, partial, and 
generalized tonic-clonic seizures (Hung & Shih 2011). Common side effects of valproic 
acid are gastrointestinal tract disturbances that include: anorexia, vomiting, tremor, and 
weight gain (Hung & Shih 2011).  
Since older generation AEDs have been around longer, there is more information 
on side effects of these medications.  
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Name of Drugs Treatment for which types of seizures 
Carbamazepine Partial and generalized seizures 
 
Clonazepam Myoclonic seizure 
 
Ethosuximide Absence seizure 
 
Phenobarbital  Partial and generalized seizures 
 
Phenytoin Partial and generalized seizures 
 
Valproic acid  Absence, partial, and generalized seizures 
Gabapentin Partial seizure 
Table 1: Antiepileptic Drugs- Older AEDs 
Table 2 contains names and treatment goals for Newer AEDs. Hung and Shih 
(2011) reported that newer generation AEDs seem to have less severe side effects and are 
better tolerated among patients, except for felbamate and lamotrigine. These newer 
generation AEDs are typically used as an adjunctive treatment for seizure disorders due 
to the lack of research of their efficacy as a single treatment for seizure disorders (Hung 
& Shih 2011). Newer generation AEDs such as gabapentin, lamotrigine, levetiracetam, 
oxcarbazepine, tiagabine, topiramate, and zonisamide are used to treat partial seizures.  
Felbamate is one of the newer AED that is used for treatment for partial seizures 
and Lennox-Gastaut syndrome in children (Hung & Shih 2011). Felbamate have been 
reported to cause an increase of concentrations of phenytoin, phenobarbital, and valproic 
acid (Hung & Shih 2011). It also causes the decrease concentration of carbamazepine 
(Hung & Shih 2011). Since Felbamate interacts with many of the other AEDs, it has 
largely been replaced by other AEDs alternatives (Hung & Shih 2011). Gabapentin is 
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used to treat partial seizures, other neuropathies, and is approved for treating postherpetic 
neuralgia (Hung & Shih 2011). Adverse effects are generally mild for gabapentin (Hung 
& Shih 2011). Specific adverse effects were not mentioned for gabapentin. Topiramate is 
used for refractory partial seizures and may reduce the effectiveness of oral 
contraceptives, increase phenytoin concentrations, and decrease valproic acid 
concentrations (Hung & Shih 2011). Levetiracetam is used for partial seizures with our 
without secondary generalization (Hung & Shih 2011). This drug has no known 
significant drug interaction with other AEDS and has mild side effects (depression) (UCB 
Pharma 2011). Tiagabine is another AED used for the treating of partial seizures. This 
AED has generally mild adverse reactions (Hung & Shih 2011). However, patients who 
use tiagabine had a recurrence of status epilepticus while receiving treatment with this 
drug (Aspen Pharma 2011) Additionally, tiagabine has no know drug interaction to other 
AEDs (Hung & Shih 2011).  Zonisamide is used as an adjunctive treatment for adults 
with partial seizures (Hung & Shih 2011). Side effects from zonisamide include 
decreased sweating, hyperthermia, and renal calculi (Hung & Shih 2011). Children have 
a more likelihood of experiencing hyperthermia relative to adults (Hung & Shih 2011). 
Other drugs such as phenytoin and carbamazepine may affect the metabolism of 
zonisamide, but this drug has no know effects on other AEDs (Hung & Shih 2011).  
Lamotrigine is used as an adjunctive treatment for refractory partial seizures and 
Lennox-Gastaut syndrome (Hung & Shih 2011). One of the major side effects for this 
AED is the risk of life-threatening rash, such as Steven-Johnson syndrome or toxic 
epidermal necrolysis (Guberman et al. 1999). These risks of life-threatening rashes 
increase when valproic acid is administered simultaneously (Hung & Shih 2011). Other 
AEDs such as carbamazepine, phenobarbital, and phenytoin have been reported to 
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increase the metabolic rate of lamotrigine, while valproic acid has been reported to 
reduce (Hung & Shih 2011). 
 
Name of Drugs Treatment for which types of seizures 
Felbamate  Partial seizure and Lennox-Gastaut 
syndrome in children 
 
Lamotrigine Partial seizure 
 
Levetiracetam Partial seizure 
 
 
Oxcarbazepine Partial seizure 
 
Tiagabine Partial seizure 
 
Topiramate  Partial seizure 
 
Zonisamide Partial seizure 
 
Table 2: Antiepileptic Drugs- Newer AEDs 
 
Family and Cultural Impact on Development 
DAILY LIVING WITH EPILEPSY 
Many individuals with epilepsy live relatively normal lives. About 80 percent are 
helped through medication and modern therapies (Shannon 2010). For those individuals 
with epilepsy who are resistant to therapies, seizures may significantly affect daily life, 
for their families, and peers. Individuals with seizures from childhood that are resistant to 
treatment tend to have a shorter life expectancy in comparison to those with epilepsy that 
respond to treatment (Shannon 2010). However, shorter life expectancy may be the cause 
of an illness that causes epilepsy, and not from the complication of having seizures in 
 17 
itself (Shannon 2010). Shannon (2010) does not address daily living of individuals with 
epilepsy and ID, but only addresses daily living of individuals with epilepsy.  
Some people with epilepsy, particularly children, may experience more behavior 
and emotional side effects (Shannon 2010). For children to experience emotional and 
behavioral changes is not uncommon for this group (Shannon 2010). Counseling services 
are available for families and caretakers to help them cope with epilepsy, as well as 
epilepsy support groups (Shannon 2010). Although Shannon (2010) does not specifically 
address individuals with ID and seizure disorders, these services may be valuable to these 
individuals’ family as well.  
For many individuals with epilepsy, having seizures may restrict their overall 
independence, but they are able to participate in some recreational activities (Shannon 
2010). Many individuals with seizure disorders are more likely able to participate in 
recreational activities, but for individuals with ID and seizure disorders this may be 
impossible due to the delays of critical developmental areas, such as motor skills.   
Sports are considered relatively safe for individuals with epilepsy. However these 
individuals must follow proper safety precautions and have supervision (Shannon 2010). 
Sports that are considered relatively safe for individuals with epilepsy such as jogging or 
football may reduce seizures because of the physical exercise (Shannon 2010). It is 
important for individuals with seizures to practice cautious and supervision recreational 
activities in order to avoid injury (Shannon 2010). From this information, individuals 
with epilepsy may live a relatively normal life and most likely would have a higher 
quality of life than individuals with ID and seizures disorders due to limitations.  
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IMPACT FOR CAREGIVERS/FAMILY AND INDIVIDUAL WITH EPILEPSY 
Caregivers and family members play an extremely important role for individuals 
with epilepsy. Caregivers and family members give insight in about to how epilepsy 
affects their family dynamics, consequences of the illness, and quality of life for 
caregivers and their loved ones (Asato et al. 2009).  According to Asato et al. (2009), 
caregivers for an individual with epilepsy are more likely to experience elevated levels of 
stress in comparison to caregivers for other chronic illnesses.  One of the issues that may 
contribute in higher stress levels is that caregivers are more involved in the child’s life. 
Caregivers are involved in making sure their loved ones are physically and mentally 
healthy and adhering to treatment. Other factors that may contribute to elevated stress 
levels for caregivers may involve parental/caregiver concern for their child’s learning and 
future development progress (Asato et al. 2009). Children who struggle in school 
subjects, such as math and reading, may not succeed in their overall academic 
achievement as the demands for higher-level tasks increases from transitioning from 
primary to secondary school.  Asato et al. (2009) does not address quality of life of 
individuals with ID and seizure disorders and their families.  
In adolescents with epilepsy, caregivers and adolescents have relatively the same 
ratings on quality of life measures in domains such as quality of life consequences of 
seizures, adherence to therapies, and productivity (Asato et al. 2009). Epilepsy in 
adolescents may hinder psychosocial and natural maturation processes that may lead to 
cognitive and behavioral challenges (Asato et al. 2009). As a result, adolescents with 
epilepsy experience a higher risk of having depression, anxiety, embarrassment, and 
cognitive and behavioral challenges (Asato et al. 2009).  
In Gallagher (2010), one of the major concerns reported for adolescents with 
epilepsy was experiencing peer stigma. Peer stigma may significantly affect the overall 
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mental health of an adolescent with epilepsy (Gallagher 2010). Since peers may often 
lack the knowledge about the nature of epilepsy, such as believing that seizures are 
contagious, it may lead to them excluding their peers with epilepsy (Gallagher 2010). 
Bishop and Boag (2006) revealed that teachers surveyed in the United States have 
stigmatizing notions regarding epilepsy and persons with seizure disorders. Interestingly, 
Bishop and Boag (2006) reported that 90 percent of teachers surveyed would like to 
know more about seizures and seizure management, although the investigators reported 
that there were resources readily available through The Epilepsy Foundation website. 
Adolescents rely heavily on their caregivers, since caregivers try their best to 
make sure their loved ones stick to daily routines. It can be challenging for caregivers if 
they try to keep their loved one safe, but at the same time, it hinders the child in 
developing independence. This can result into increase in depression, behavioral 
problems, and anger (Asato et al. 2009). This may also apply for individuals with ID and 
seizure disorders since the majority of the levels of intellectual disabilities are unable to 
live independently and require supervision from caregivers.   
In addition to emotional and psychological effects on family members caring for 
individuals with epilepsy, financial burdens are important issues. According to Odell et 
al. (2007), the average financial cost of emergency outpatient services averaged about 
$3,255 and in-patient emergency services averaged about $12,555. These emergency 
services accounts for the direct cost of seizure disorders that include emergency medical 
services, diagnostic testing, treatment procedures, medical treatment, follow-up costs, and 
treatment of other comorbidities (Odell at al. 2007). There are also indirect costs, which 
include the cost of time spent away from work, absence from school, or parents or 
caregivers losing their jobs (Odell et al. 2007). It is also important to acknowledge that 
individuals with epilepsy have incomes that are less than the general population average 
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(Odell et al. 2007). This may lead to a more financial burden since each year the rise in 
health care costs and may make it difficult for individuals with epilepsy and their family 
members (Odell et al. 2007). Since Odell et al. (2007) did not mention financial burdens 
specifically for individuals with ID and seizure disorders, it may be challenging to 
estimate the financial burdens for them and their families. As mentioned earlier, 
individuals with ID and seizure disorders may have other comorbidities that may require 
treatment, which potentially may lead to a greater financial burden than individuals with 
only seizure disorders.  
Overall, many factors play a role in how epilepsy affects the quality of life (QOL) 
for the individual with epilepsy and their family. Because these studies did not mention 
QOL for individuals with ID and seizure disorders, it may be challenging to evaluate the 
QOL impact for these people and their families. However, Hoare (1993) reported that 
individuals with early onset intractable epilepsy, in addition to other disabilities, have an 
extremely negative effect on their QOL. Factors that may influence QOL for individuals 
with seizures and their families are dependent on severity of the seizure, management of 
seizures, adverse side effects of AEDs, adjustment to the child’s overall development, 
and limitations on family life (Hoare 1993).     
EFFECTS OF SEIZURES ON EDUCATION  
Researchers have concluded that epilepsy disorders may affect academic 
performance in individuals with seizures (Gallagher 2011). Since the impact of seizure 
disorders varies in each individual due to the type, severity, and frequency of seizures, it 
is difficult to generalize the process of learning of each individual. Gallagher (2011) did 
not mention information regarding the education status of individuals with ID and seizure 
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disorders, which makes it challenging to determine specifically the effects of seizures on 
education for this group.  
 The learning process of each individual is comprised of a series of abilities, such 
as an individual’s cognitive ability, attention skills, concentration skills, communication, 
listening, memory, and critical thinking skills (Gallagher 2011). It is also important to 
note that each individual may have difference experiences and beliefs that would 
influence his overall academic performance. The effects of seizures may result in the 
impairment of emotional and cognitive abilities, which may hinder productivity in the 
work place or school environment. Gallagher (2011) did not mention socio-economic 
status or parental education, but these factors may play a major role in the level of 
experience each individual may acquire.   
Austin et al. (1999) have reported that children may have normal IQs before their 
first seizure. They also found that children with epilepsy had more difficulty with math, 
reading, and language in school relative to their peers. Children with severe epilepsy 
were more likely to be behind than their typically developing peers. Since epilepsy 
affects different aspect of cognition due to the nature of the disorder, these effects may 
have a negative impact for academic success (Austin et al. 1999). In order to keep 
students moving towards academic success, it’s important for students with epilepsy to be 
surrounded by supportive teachers, mentors, and parents.   
Many of these reports exclude information about individuals with ID and seizure 
disorders.  Since there is a lack of information about the QOL and effects of seizures on 
education, it is difficult to determine or generalize the overall QOL and education status 
for these individuals and their families.   
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EFFECTS OF SEIZURES ON SPEECH AND LANGUAGE DEVELOPMENT 
Speech and language development play a critical role in the academic success of 
children, so it is important to understand how epilepsy affects this critical aspect of 
development in order to plan appropriate accommodations with teachers, families, and 
other practitioners. If there is a delay in speech and language development as a result of 
epilepsy, it may negatively impact a child’s academic success, which may also affect 
overall psychosocial and emotional health. Since one of the goals in this report is to 
address how seizure disorders affect speech and language development, it is important to 
discuss the relationship between epilepsy and speech and language. In this meta-analysis, 
research regarding the effects of seizure disorders in individuals with ID on speech and 
language development was not found. All of the research found in this topic excluded 
individuals with other neurological comorbidities. Caplan (2002), Caplan et al. (2008; 
2009), Sellasie et al. (2008), Strekas et al. (2013) did not mention the reason for 
excluding this population, but it may be because individuals with ID may have limited 
communication skills based on their level of disability. 
In a study that examined language development in children with pediatric 
epilepsy, Caplan et al. (2009), found that children with epilepsy scored one standard 
deviation lower than their age-match control group in language assessments. Children 
were 6 to 15.5 years in age with history of seizures, but did not include children with ID 
and seizures.  As the age of the children increased, children with epilepsy had more 
language impairments compared to their peers (Caplan et al. 2009). As children transition 
from primary schools to secondary schools, there is a higher demand on their language-
based learning skills, so that may be one of the reasons for the difference (Caplan et al. 
2009). Based on Caplan and colleagues’ findings, children may not have the same 
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linguistic deficits because these deficits may be dependent on other factors, such as age, 
socioeconomic status, and duration of illness.   
Selassie et al. (2008) examined the expressive and receptive language, oral motor 
ability, memory, and intelligence of children 20 six-year-old children with epilepsy. They 
excluded all children with neuro-impairments or learning disabilities. The authors found 
statistically significant differences between expressive and receptive grammar, and 
receptive vocabulary. However, Selassie et al. (2008) found that children with epilepsy 
scored a lower performance IQ, oral motor ability, articulation, and short-term memory 
compared to children without epilepsy. Since this study only included participants who 
were six-years-old, it may explain why there was not a significant difference between 
expressive and receptive grammar. As mentioned earlier, language-based skills may not 
be as demanding in children in this particular age range compared to older children and 
adolescents.   
Another important aspect of language development is the narrative ability of 
children. Strekas et al. (2013) evaluated the narrative abilities of 25 children with 
epilepsy (CWE). The CWE were assessed through narrative assessments and then 
compared to children without epilepsy. The children ages ranged from 50 to 155 months 
and did not have other neurological conditions or syndromes. Strekas et al. (2013) found 
CWE scored poorly on structural analysis of storytelling and listener judgment compared 
to their peers. Listeners’ perceptions of CWE’s narratives production were judged to be 
less coherent in terms of syntax and lexically complexity (Strekas et al. 2013). CWE who 
had a more recent onset of seizures did not have the same functional deficits in language 
production compared to CWE who had chronic seizures. As for speech perception, CWE 
did not show differences in prosody and fluency from listeners’ perception (Strekas et al. 
2013). It was noted that older children’s narratives were longer and more complex in 
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which requires higher-ordered tasks such as planning and organization (Strekas et al. 
2013).  
In addition to how epilepsy may affect speech and language, research findings 
have shown that children with epilepsy may have difficulties with formulating and 
organizing thoughts that may affect their overall social communication skills. Caplan 
(2002) examined the social communication skills of 92 children with complex partial 
seizure disorder, 51 children with primary generalized epilepsy, and 117 children 
developing typically. All the participants were 5 to 16.9 years in age. The found that 
children with complex partial seizures were found to have cohesion deficits and formal 
thought disorders. For example, children were unable to tie together continuous clauses, 
and sentences (Caplan et al. 2002). Meanwhile, children with partial generalized epilepsy 
had mild cohesion deficits. Having lack of cohesion and thought process may severely 
impact academic success because language-based skills demands increases as children 
transition from primary school to secondary school as mentioned earlier. Caplan et al. 
(2002) concluded that children with CPS and PGE may have deficits in communication 
skills.   
Given the lack of research for speech and language development in individuals 
with ID and seizure disorders, this meta-analysis will investigate the side effects of AEDs 
on speech and language development in individuals with ID and seizure disorders. 
Specifically, the aim of this meta-analysis is to provide a resource for clinicians about the 
possible side effects of AEDs that used for treating individuals with ID and seizure 
disorders. It is important for clinicians to understand what types of side effects were 
reported with various seizure medications and how seizure medication side effects may 
impact speech-language pathologist practitioners in assessing and treating individuals 
with ID. 
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METHODS 
For this meta-analysis of the effects of seizure disorders and medication on speech 
and language development in children with ID, a literature search was conducted by 
accessing databases through the University of Texas at Austin library. Databases that 
were used to access articles include Medline, CINAHL, PubMed, and ERIC. Google 
Scholar was also used to find research articles for this literature review. Although articles 
on Google Scholar required payment, the title of articles that were searched through 
Google Scholar, were input into the search engine of the University of Texas at Austin’s 
library. The inclusion criteria of the review had to include individuals with ID who are 
taking AEDs and have epilepsy. Since the articles found were limited, all the articles 
were included if the participant was taking at least one AED.  
Search terms that were used for the meta-analysis included, intellectual 
disabilities, epilepsy, seizure disorders, mental retardation, anticonvulsants side effects, 
behavioral side effects, and developmental disabilities, and speech and language.  Other 
search terms were used to find more articles because with those search terms above, a 
limited number of article were located. From there, other search terms included 
oxacarbazepine, carbamazepine, valproic acid, phenytoin, levetiracetam, topiramate, 
phenobarbital, and lamotrigine.  Articles were also found through the reference lists from 
other articles and seizure medication reviews.  
A total of 60 articles that included children with intellectual disabilities and also 
included information about medication side effects were identified in the search. Of the 
60 articles found, 42 of those were excluded in the review for the following reasons: 
some of the medications used to treat individuals with ID with epilepsy were not AEDs; 
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the literature included individuals with ID, but did not provide specific results pertaining 
to them, and some literature did not include individuals with ID.  
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RESULTS 
OVERVIEW 
This section will discuss the overview of the findings of 19 identified articles. 
Nineteen articles met the inclusion criteria. The 19 articles reviewed involved the use of 
AEDs in treating seizure disorders in individuals with ID and seizure disorder and side 
effects. Seventeen articles were identified as experimental studies and two articles were 
identified as case reports. The number of participants in case studies was two, and the 
number of participants in the studies was 1,754. Eighteen of 19 articles measured 
behavioral side effects and non-behavioral side effects from AEDs. Seven of 19 articles 
were based on observation from investigators or from either medical, staff, or caregiver 
reports. Two of the 19 studies reviewed, investigated the effects of AEDs on social skills 
and psychopathological adverse events in individuals with ID with seizure disorders. 
Thirteen studies only included individuals with ID and seizure disorders. Meanwhile, six 
studies included individuals with ID and seizure disorders and individuals with seizure 
disorders in their study. Five of 19 articles reviewed did not analyze their data with any 
measure of statistical analysis. However, 14 of 19 articles used statistical analysis in 
evaluating their data.  
PARTICIPANT SELECTION 
Based on the findings of the 19 articles reviewed, inclusion and exclusion criteria 
were not used in participant selection in many of the articles. Participants included in the 
studies included either only adults or children and adolescents. A few studies included 
individuals with seizure disorders along with participants with ID and seizure disorders. 
Harbord (2002), Khurana et al. (1996), and McKee et al. (2004) included only children, 
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adolescents or both within their participant selection. However, Gidal et al. (2000) 
included children and adults in their evaluation of LTG therapy.  
DATA COLLECTION AND ANALYSIS 
Data collection and analysis in these articles used a variety of different methods 
that were not consistent across studies. Data – based studies reviewed used a variety of 
scales and checklists.  Ettinger et al. (2008), McKee et al. (2004), and Martin et al. (2009) 
used the Aberrant Behavior Checklist as one of their data collection methods. 
Helmstaedter et al. (2008) was the only study that used the Barratt Impulsiveness Scale-
11and Fragebogens zur Personlichkeit be zerebralen Erkrankungen in their data 
collection. Coppola et al. (2008) used Holmfrid Quality of Life Inventory. Matson, Luke, 
and Mayville (2004) and Martin et al. (2009) and Matson et al. (2001) used Matson 
Evaluation of Drug Side Effects, Hurtado et al. (2006) used Challenging Behavior Scale 
and Ritualistic Behavior Rating Scale. McKee et al. (2004) Habilitative Improvement 
Scale in the evaluation of side effects in AEDs.  Based on the review of the data 
collection and analysis, data-based studies did not have a uniform or consistent method of 
collection data and analysis. 
REPORTED AEDS SIDE EFFECTS 
Reported side effects from AEDs in the 19 articles reviewed included: aggression, 
hyperactivity, agitation, irritability, self-injurious behaviors, increased energy, disruptive 
vocalizations, psychotic-like behavior, drowsiness, fatigue, decrease in alertness, 
concentration, and appetite, lethargy, paranoia, stereotypy, increase in seizures, 
disorientation, abnormal movement, rash, hirsutism, tremor, headaches, mood swings, 
gastrointestinal symptoms (i.e., vomiting, abdominal pain), slurred speech, abnormal 
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white blood cell count, sleep disorders,  memory problems, infections (ear, nose and 
throat), and mental state disorders (i.e., depression, paranoia).  
OLDER AND NEWER GENERATION AEDS 
Fourteen articles reviewed used newer AEDs (Levetiracetam, Topiramate, 
Gabapentin, Lamotrigine) as a treatment for seizure disorders or as an adjunctive to 
seizure treatment. This may be the result of increased research in newer generation AEDs 
in relatively recent years. Only three articles reviewed involved in the treatment of 
seizure disorders using older generation AEDs (phenytoin, carbamazepine, valproic acid, 
clonazepam). Two articles reviewed incorporated both newer and older generation AEDs 
in their treatment evaluation. All participants had exposure to more than one AED during 
the time of treatment. All participants included in the articles were taken at least one 
AED in their treatment regimen.  
GOALS OF THE STUDIES 
The main goals of the 19 articles reviewed involved investigating or observing the 
behavioral side effects, the efficacy, tolerability, and safety of AEDs.  Other goals of the 
studies reviewed included: examining effects of AEDs on social skills, the relationship in 
AEDs and antipsychotic medication, and cognitive or non-behavioral side effects of 
AEDs.  A summary of each article is located in the appendix. The summary and critique 
of the literature will be discussed in the next section. 
A brief summary and critique of the literature will be discussed in this section. 
Summary of the 19 articles and references are available in the appendix section. The 
critique will evaluate: criteria of participant recruitment, cultural component, language 
status of the participants, additional services the participants may have received (i.e. 
physical therapy, speech therapy), data collection, and data analysis. 
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CASE STUDIES 
Table 3 displays the summary and critique of the two case studies reviewed. 
Coffey (2013) described the use of Phenytoin in an individual with Autism, seizures, and 
ID to resolve self-injuries. An extensive case history of the participant was provided that 
included: behavior problems, behavioral interventions, hospital visits, additional services 
and medications. However, the following information was excluded: inclusion and 
exclusion criteria, cultural information, and where was the language information. Before 
treatment, it was reported that the participant received behavior therapy that was 
ineffective. Coffey (2013) reported when Phenytoin was added to the participant’s 
medication regimen, the self-injurious behaviors resolved, but data analyses were not 
conducted. Since the data collect was observational, baselines measures were also not 
included.  
Kalachnik et al. (2003) provided descriptions of an individual with ID and seizure 
disorders have exacerbated behaviors when using Clonazepam. Similarly to Coffey 
(2013), the following information was missing: inclusion or exclusion criteria, cultural 
information, where the authors obtained language information, and additional services. 
Although Kalachnik et al. (2003) and Coffey (2013) reported information about their 
participants receiving additional services, the frequency and who implemented these 
additional services was not described. Both studies reported the language status of their 
participants. Kalachnik et al. (2003) reported “very good” receptive language skills, but 
did not provide information regarding expressive-language skills, while the participant in 
Coffey (2013) was described as nonverbal. Coffey (2013) and Kalachnik et al. (2003) 
both used observational data and treatment history. In contrast, Kalachnik et al. (2003) 
used a specific criterion in order to record tantrum behaviors, while Coffey (2013) did not 
establish specific criteria to record data.  
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Article Participant(s) Side Effects Critique 
Coffey 
(2013)  
21-year-old nonverbal 
male with Autism, 
ID, and seizure 
disorder.  
Received behavioral 
interventions, but 
ineffective 
Resolved self-
injurious behaviors: 
heading banging, 
biting  
Missing information: 
participant selection criteria, 
patient characteristics, cultural 
information, data analysis, and 
outcome measures, additional 
services  
Kalachnik et 
al. (2003) 
49-year-old male with 
ID and tonic-clonic 
seizures. 
History of 
challenging 
behaviors.  
Receptive language 
was described as 
“good” 
Exacerbated self-
injurious behaviors 
Aggression towards 
other people: hitting, 
biting, head-butting 
Aggression towards 
property  
Limited demographic 
information 
Missing information: cultural 
component, language 
assessment, procedural, 
baseline measures, seizure 
frequency, definition of 
significance  
 
Table 3: Summary of Case Studies 
 
SOCIAL SKILLS AND PSYCHOLOGICAL STUDIES 
Table 4 provides a brief summary and critique of one article that examined the 
social skills and one study examined psychopathological adverse events (PAEs) of 
participants with ID and seizure disorders. Matson, Luke, & Mayville (2004) and Mula, 
Trimble, & Sander (2004) did not include: participant selection criteria, cultural 
information, language status, and additional services. Mula, Trimble, & Sander (2004) 
used the International League Against Epilepsy (ILAE) classification for seizure and 
seizure types; however, Matson, Luke, & Mayville (2004) did not provide information 
about seizure classification. Both studies included demographic information such as sex, 
age, and ethnicity.  Matson, Luke, & Mayville (2004) and Mula, Trimble, & Sander 
(2004) both conducted data analyses. Matson, Luke, & Mayville (2004) used an Analysis 
of Variance (ANOVA), but baseline, outcome measures, and significance were not 
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defined. In contrast, Mula, Trimble, & Sander (2004) reported baseline and outcome 
measures using the Fisher’s exact test, Pearson coefficient, and ANOVA, but did not 
define significance. Matson, Luke, & Mayville (2004) used The Matson Evaluation of 
Social Skills for Individuals with Severe Retardation (MESSIER). Mula, Trimble, & 
Sander (2004) used the DSM-IV to classify the psychopathological adverse events (PAEs) 
in 118 patients with ID and with LEV treatment. Matson, Luke, and Mayville (2004) 
reported a significantly lower score in the positive nonverbal subscale in the Phenytoin 
group, but did not include additional information about the language abilities of the 
group.   
 
Article Participant(s) Side Effects Critique 
Matson, 
Luke, and 
Mayville 
(2004) 
130 participants (60 
male, 70 female) with 
ID and seizure 
disorders. 
Participant 
characteristics were 
provided. 
No side effects 
reported. 
Missing information: 
participant selection criteria, 
cultural information, outcome 
measures, definition of 
significance, how seizure types 
were classified, language 
status, and additional services 
Mula, 
Trimble, and 
Sander 
(2004)  
118 participants (64 
males, 54 females) 
with ID.  
Demographic and 
patient variables 
provided.  
DSM-IV criteria used 
for PAEs.  
PAEs  
Agitation  
Anger 
Hostile Behavior  
Missing information: 
Patient selection criteria, 
cultural information, who 
conducted IQ testing, language 
assessment, data collection, 
additional services, and 
caregiver role 
 
Table 4: Summary of Social Skill and Psychological Effects Studies  
 
OBSERVATIONAL STUDIES 
Table 5 provides a summary of articles that were observational in nature, formal 
or informal assessments, or collected data from medical reports. Coffey (2013), 
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Kalachnik et al. (2003), and Mula, Trimble, and Sander (2004) were described in the 
previous section.  
Singh & White-Scott (2002) examined the usefulness of Topiramate (TPM) in 20 
patients with ID and seizure disorders. Unlike Coffey (2013) and Kalachnik et al. (2003), 
Singh & White-Scott (2002) included participant selection criteria, detailed 
demographical information that included seizure frequency and type. However, cultural 
information, language abilities, data analyses, and additional services were not 
mentioned. Additionally, level of ID of each participant was determined by a 
combination of IQ scores and psychological evaluation. Since reports were rated by the 
investigators, caregiver ratings may have provided a more accurate representation of 
participants’ overall improvement.  
Harbord (2002) reviewed the AEDs histories of 216 children and adolescents with 
epilepsy to determine the incidence of behavioral and non-behavioral significant side 
effects (SSE). Similarly to Coffey (2013) and Kalachnik et al. (2003), Harbord (2002) did 
not include: participant selection criteria, data analyses, cultural information, and patient 
characteristics. Harbord (2002) also did not describe language abilities or if the 
participants received additional services during the study that was similar to Singh & 
Scott-White (2002) findings. Data was collected through parent reports that included: 
which AEDs were used and which AEDs were discontinued due to SSE. Harbord (2002) 
did not describe behavioral SSEs, but did not describe non-behavioral SSEs.  
Dinkelacker et al. (2003) described the emergent of adverse effects of LEV in 33 
patients with refractory epilepsy. Demographic and patient characteristics were provided. 
The following information was not included: cultural information or language abilities of 
participants, level of ID of participants, additional services, baseline measures, and data 
analyses. Dinkelacker et al. (2003) reported success with LEV therapy and side effects, 
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but results were not corroborated with baseline measures. Dinkelacker et al. (2003) and 
Singh & Scott-white (2002) were the few studies in this section that used participant 
selection criteria.  
Bootsma et al. (2004) examined the use of TPM in 470 participants in a real-life 
setting. Similar to the studies discussed previously, Bootsma et al. (2004) did not include: 
cultural information, language status, participant selection criteria, additional services, 
and where was the ID information obtained. Bootsma et al. (2004) classified seizure 
types according to the ILAE guidelines that were also used in Singh & Scott-White 
(2002). Bootsma et al. (2004) reported significant findings based on patient records, but 
did not define what was considered significant. Although the investigators did not assess 
language abilities of the participants, dysphasia was reported in the results and the 
investigators did not provide further details in regards to where the language measure was 
obtained.  
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 Table 5: Summary of Observational Studies 
 
Article Participant(s) Side Effects Critique 
Coffey (2013)  21-year-old 
nonverbal male with 
Autism, ID, and 
seizure disorder.  
Received behavioral 
interventions, but 
ineffective 
Resolved self-
injurious behaviors: 
heading banging, 
biting  
Missing information: 
participant selection criteria, 
patient characteristics, 
cultural information, data 
analysis, and outcome 
measures  
Kalachnik et al. 
(2003) 
49-year-old male 
with ID and tonic-
clonic seizures. 
History of 
challenging 
behaviors.  
Receptive language 
was described as 
“good” 
Exacerbated self-
injurious behaviors 
Aggression towards 
other people: hitting, 
biting, head-butting 
Aggression towards 
property  
Limited demographic 
information 
Missing information: 
cultural component, 
language assessment, 
procedural, baseline 
measures, seizure 
frequency, definition of 
significance  
Singh and 
White-Scott 
(2002) 
20 participants (12 
males, 8 females) 
with ID or DD.  
Participant selection 
criteria provided.  
 
Behavior problems, 
decreased alertness, 
drowsiness, increase 
in seizures, abnormal 
movement, 
disorientation, 
unsteadiness, 
pneumonia, low 
platelets, and low 
white blood cell 
count  
Missing information: what 
assessments were used to 
classify IQ; additional 
services; who classified 
seizure type; how data was 
analyzed, baseline for 
global improvement, 
language abilities, cultural 
information, data analysis, 
and definition of 
significance  
Harbord (2002)  216 children and 
adolescents (107 
girls, 109 boys)  
All had seizure 
disorders.  
IQ testing used to 
determine 
participants with ID.  
 
Behavioral side 
effects (not 
described) 
Non-behavioral side 
effects: rash, 
drowsiness, 
Hirsutism, tremor, 
increase seizures, 
headaches, lethargy, 
and excess weight  
Limited demographic 
information. 
Missing information: patient 
characteristics, cultural 
component, IQ tests and 
administration, participant 
selection criteria, data 
collection, behavioral side 
effects, additional services, 
and seizure type  
Dinkelacker et 
al. (2003) 
33 patients with 
history of refractory 
epilepsy. 
Patient 
characteristics and 
demographic 
information were 
provided 
Increased 
aggression, increased 
irritability, fatigue, 
sleep disorders, 
memory problems, 
gastrointestinal 
adverse effects, and 
depression 
Missing information: 
cultural component, level of 
ID, baseline and outcome 
measures, language status, 
data analysis, additional 
services, how were adverse 
effects defined/recorded 
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     Table 5: Summary of Observational Studies (Continued)  
 
EXPERIMENTAL STUDIES  
Hanzel et al. (2000) explored the relationship between barbiturate AEDs and 
antipsychotic medications in seven individual with ID and seizure disorders. Participants 
were diagnosed with ID according to the DSM-IV criteria (Hanzel et al. 2000). The 
following information that was not included: assessment of language abilities, additional 
services, baseline measures, participant selection criteria, and cultural information. Data 
collection was obtained by index behaviors measured by residential staff or unit 
psychologist; however, index behaviors were not defined. Data analyses were conducted 
using an a priori analysis; Wilcoxon matched-pairs signed-ranks test, and t-test (Hanzel 
et al. 2000). Hanzel et al. (2002) reported decrease in behavioral problems, but baseline 
measures were not conducted to verify the findings.  
Helmstaedter et al. (2008) examined the behavioral changes in patients receiving 
Levetiracetam (LEV) and evaluated the effects of LEV on impulse control and aggression 
Bootsma et al. 
(2004) 
470 participants 
were identified (160 
patients with ID) 
through medical 
information system. 
Demographic and 
patient 
characteristics 
provided. 
Weight loss  
Mood problems 
Gastrointestinal 
problems  
Dysphasia 
Cognitive slowing 
Missing information: 
cultural component, Level of 
ID, language abilities, 
definition of significance, 
additional services, 
participant selection criteria 
Mula, Trimble, 
and Sander 
(2004)  
118 participants (64 
males, 54 females) 
with ID.  
Demographic and 
patient variables 
provided.  
DSM-IV criteria 
used for PAEs.  
 
PAEs  
Agitation  
Anger 
Hostile Behavior  
Missing information: 
Patient selection criteria, 
cultural information, who 
conducted IQ testing, 
language assessment, data 
collection, additional 
services, and caregiver role 
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in 288 outpatients with epilepsy. As described previously in Hanzel et al. (2000), 
Helmstaedter et al. (2008) also did not include the following information: participant 
selection criteria, baseline measures, cultural information, language abilities, and 
additional services. Helmstaedter et al. (2008) was one of the few studies that had a 
control and experimental group; however, data analyses were only provided for the 
control group, since the experimental group did not match. Helmstaedter et al. (2008) 
obtained data by using the Barratt Impulsiveness Scale-11 and Fragebogens zur 
Personlichkeit be zerebralen Erkrankungen (FPZ) questionnaire (Helmstaedter et al. 
2008). Similarly to Hanzel et al. (2000), Helmstaedter et al. (2008) did not report baseline 
measures and outcomes to validate their findings.  
Coppola et al. (2008) assessed the behavioral and cognitive effects in 34 
participants with ID and seizure disorders following treatment with Topiramate (TPM). 
Contrast to Hanzel et al. (2000) and Helmstaedter et al. (2008), Coppola et al. (2008) 
used inclusion and exclusion criteria in participant selection. Additionally, ID diagnoses 
were evaluated according to DSM-IV criteria, as well as severity of ID of the participants. 
Similarly to Hanzel et al. (2000) and Helmstaedter et al. (2008), Coppola et al. (2008) did 
not include cultural information, baseline measures, additional services information, and 
language status of the participants. Data was measured and collected from caregivers by 
using the Holmfrid Quality of Life Inventory. Data analysis was evaluated by SSPS 10.0 
software for Windows (Coppola et al. 2008). As identified in previous studies described, 
Coppola et al. (2008) reported results that lacked baseline and outcome measures.  
Beran and Gibson (1998) examined the emergence of provoked aggressive 
behavior in treatment with Lamotrigine (LTG) in 19 participants with ID and seizure 
disorders. The following information was missing: participant selection criteria, cultural 
information, additional services information, language abilities, and level of ID. The 
 38 
following missing information was similar to the findings in Helmstaedter et al. (2008), 
and Hanzel et al. (2000). Results were provided through description of behavior observed 
in each participant. Beran and Gibson (1998) reported results that were strictly 
observational from parent reports, but did not report how patients’ behavior was prior to 
LTG therapy.  
Ettinger et al. (1998) described the significant positive or negative psychotropic 
effects of LTG in 7 individuals with ID and seizure disorders. Similarly to Beran and 
Gibson (1998), Ettinger et al. (1998) did not include the following information: 
participant selection specification, baseline measures, cultural information, additional 
services information, and data analyses. Data was collected and recorded by supervising 
staff or caregivers and then reported to investigator; however, Ettinger et al. (1998) did 
not conduct data analyses. Ettinger et al. (1998) provided detailed narratives case reports 
for 3 of 7 participants were reported in the results, but did not provide reports for the 
remaining participants and did not specify the reason for this. Information from the case 
report indicated that two participants had some vocalization and one participant was 
nonverbal, but the language abilities of the rest of the participants were not reported.   
Khurana et al. (1996) examined the efficacy, tolerability, and safety of adjunctive 
Gabapentin in 32 children with refractory partial epilepsy. Similarly to Coppola et al. 
(2008), Khurana et al. (1996) identified participants according to inclusion and exclusion 
criteria through patient records at a children’s hospital. The following information was 
not included: cultural information, additional services information, level of ID, and 
seizure type. Although information regarding diagnoses of ID and seizure disorders was 
provided, investigators did not provide information as to who diagnosed these 
participants. Investigators used a scale to rate adverse events; however, the rating scale 
did not appear to be representative in terms of the level of impact from the AED’s side 
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effects. As mentioned earlier in Singh & Scott-White (2002), it may be more of an 
accurate representation if the caregiver coded the adverse event ratings rather than the 
investigators. Khurana et al. (1996) reported outcome measures, but did not establish 
baseline measures. 
Gidal et al. (2000) evaluated the efficacy of LTG in 44 participants with ID and 
seizure disorders. Gidal et al. (2002) only used inclusion criteria in participant selection. 
Similarly to articles discussed previously, Gidal et al. (2003) did not provide the 
following information: exclusion criteria, additional services information, cultural 
information, and language abilities. Adverse drug effects data were obtained from nurses 
and medical reports and Student t-test was used to analyze the data collected (Gidal et al. 
2000). In contrast to previous studies mentioned, Gidal et al. (2000), reported results that 
were corroborated with pre- and post measures.  
Matson et al. (2001) provided descriptive characteristics of 248 participants with 
ID and seizure disorders and examined the side effects of AEDs. Matson et al. (2001) did 
not provide the following information: participant selection criteria, cultural information, 
additional services, language abilities, seizure type, or who diagnosed ID. Although 
information regarding who diagnosed the participants with ID was not mentioned, ID 
diagnoses were evaluated according to the DSM-IV criteria (Matson et al. 2001). Matson 
et al. (2001) reported limited information regarding language abilities. Authors reported 
that most of the participants were nonverbal, but did not mention what was used to assess 
language. Matson et al. (2001) reported that all of the participants had other 
comorbidities, but they did not mention further information about treatment. Clinical 
psychologists administered the Matson Evaluation of Drug Side Effects (MEDS) (Matson 
et al. 2001). Matson et al. (2001) analyzed data through descriptive analyses and also 
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used the ANOVA to analyze data (Matson et al. 2001). Similar to Khurana et al. (1996), 
Matson et al. (2001) reported significant findings, but did not include baseline measures.  
Hurtado et al. (2006) evaluated the behavioral changes in 35 participants with ID 
or acquired brain damage with refractory epilepsy on LEV therapy. Hurtado et al. (2006) 
did not include the following information: participant selection criteria, cultural 
information, language assessments, seizure type and level of ID. Although the 
investigators did mention that the language status was derived from neurological reports, 
there was no additional information regarding which type of assessment was used. 
Hurtado et al. (2006) conducted data analyses through the Wilcoxon signed rank test, 
Mann-Whitney U Test, Spearman P, and Pearson r. As mentioned in Khurana et al. 
(1996) and Matson et al. (2001), Hurtado et al. (2006) reported improvement in patient 
ratings; however, baseline measures were missing.  
Martin et al. (2009) examined the efficacy and behavioral effects of TPM in 29 
participants with ID and seizure disorders. Martin et al. (2009) used inclusion criteria, but 
did not use exclusion criteria in the selection of participants. Similar to Hurtado et al. 
(2006), Martin et al. (2009) did not include the following information: cultural 
information, additional services, or who diagnosed ID. Classification of ID diagnoses was 
evaluated according to ICD-10 criteria, but the authors did not mention who evaluated 
these participants (Martin et al. 2009). Similar to Matson, Luke, and Mayville (2004), 
Martin et al. (2009) used the MESSIER for evaluating social skills and behavioral 
disturbance was measured through ABC (Martin et al. 2009). Adverse events were coded 
according to the WHO Adverse Reaction Terminology, and responder rates were based on 
caregivers’ diaries (Martin et al. 2009). Similar to Gidal et al. (2000), Martin et al. (2009) 
reported results that included baseline measures.  
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McKee et al. (2004) examined the effects of add-on Lamotrigine (LTG) treatment 
on seizure reduction, safety, tolerability, and behaviors in 22 participants with ID and 
seizure disorders. As mentioned in Coppola et al. (1998) and Khurana et al. (1996), 
McKee et al. (2004) used inclusion and exclusion criteria in the selection of participants. 
Similar to Martin et al. (2009), McKee et al. (2004) did not include: cultural information, 
additional services information, and language status. Epilepsy was diagnosed according 
to the ILAE guidelines and severity of ID was diagnosed according to the DSM-IV 
Revised criteria (McKee et al. 2004). Caregivers also completed the Habilitative 
Improvement Scale (HIS) (McKee et al. 2004). Investigators coded the adverse events, 
but they did include more information regarding reported adverse events. Investigators 
used appropriate measures in evaluating these participants. Since the investigators 
completed the ABC ratings, the results may reflect a more accurate representation if the 
caregivers completed the ABC ratings.  Similar to Gidal et al. (2000), McKee et al. (2004) 
included baseline measure to support their findings.   
 
Article Participant(s) Side Effects Critique 
Hanzel et al. 
(2000)  
7 individuals with ID 
and seizure disorders 
 
Self-injurious behavior, 
property destruction, 
disruptive 
vocalizations, verbal 
threats and reported 
decrease in aggression 
Missing information: language 
abilities, participant selection 
criteria, cultural information, 
additional services  
 
Table 6: Summary of Experimental Studies  
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Table 6: Summary of Experimental Studies (Continued)  
 
Helmstaedter 
et al. (2008) 
288 participants were 
divided in a control 
and experimental 
group  
Demographic and 
patient characteristics 
were provided  
Aggression  
Better concentration 
Increased energy 
Missing information: 
participant selection criteria, 
limited demographic 
information, cultural 
information, who gave 
participants ID diagnoses or 
level of ID, baseline and 
outcome measures not 
included, language abilities, 
and additional services  
Coppola et al. 
(2008) 
34 participants (16 
males, 13 females) 
with ID and seizure 
disorder 
Aggressiveness 
Psychotic-like 
behavior, decreased in 
appetite, tiredness, 
drowsiness, decrease in 
concentration and 
alertness 
Missing information: additional 
information, cultural 
information, language abilities, 
baseline and outcome measures 
Beran and 
Gibson (1998) 
19 participants (16 
male, 3 women) with 
ID and seizure 
disorder 
Aggressive behavior, 
paranoia, withdrawn, 
lethargy, depression  
Limited demographic 
information. 
Missing information: cultural 
component, measurement of 
adverse behavior, language 
abilities, level of ID, seizure 
type, additional services, 
participant selection criteria, 
data analysis 
Ettinger et al. 
(1998) 
7 participants with ID 
(5 of 7 had Lennox-
Gastaut syndrome)  
Increased in irritability, 
hyperactivity, and 
stereotypy  
Limited demographic 
information.  
Missing information: patient 
selection criteria, case reports 
for rest of participants, cultural 
information, level of ID, 
additional services, baseline 
and outcome measures, data 
analysis, language abilities of 
rest of participants  
Khurana et al. 
(1996)  
32 children with 
refractory partial 
epilepsy  
Rash, hyperactivity, 
increased aggression, 
violent outbursts, mood 
swings, increased 
impulsivity and 
irritability 
Limited participant 
demographics.  
Missing information: cultural 
information, level of ID, 
language abilities, baseline and 
outcome measures, additional 
services, 
Vague coding scale  
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Table 6: Summary of Experimental Studies (Continued)  
 
Gidal et al. 
(2000)  
54 participants (25 
men, 19 women) with 
profound ID and 
seizure disorder. 
Self-injurious 
behavior, 
gastrointestinal 
symptoms  
Limited demographic data 
Missing information: cultural 
component, language status, 
additional services 
Matson et al. 
(2001) 
248 participants with 
ID and seizure 
disorders were 
divided into one 
control and 
experimental group  
Abnormal white blood 
cell count, disturbed 
gait, balance 
disorders, self-
injurious behaviors 
Missing information: 
participant selection criteria, 
cultural information, 
additional services, seizure 
type, treatment of other 
comorbidities  
Hurtado et al. 
(2006) 
35 participants with 
refractory seizures.  
Demographic and 
patient characteristics 
were provided.  
Problem behaviors, 
verbal aggression, 
reduction in seizures  
Limited demographic 
information.  
Missing information: patient 
selection criteria, language 
assessment, level of ID, 
additional services, 
challenging behavior data, 
baseline and outcome 
measures 
Martin et al. 
(2009)  
29 participants with 
Cerebral Palsy. 
Participant 
characteristics 
provided. 
Gastrointestinal 
disorder, nervousness, 
tiredness, injuries, 
mental state disorders  
Limited demographic 
information.  
Missing information: 
language abilities, cultural 
information, patient selection 
exclusion criteria, where IQ 
information obtained, 
additional services 
McKee et al. 
(2004)  
22 participants with 
ID and seizure 
disorder 
Vomiting  
Somnolence  
Abdominal pain  
Dizziness  
Missing information: cultural 
information, language status, 
additional services  
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DISCUSSION 
 
Based on the findings of the 19 article reviewed, AEDs may cause a variety of 
adverse side effects in individuals with ID and seizure disorders. The most common side 
effects from AEDs in individuals with ID and seizure disorders included: aggression, 
irritability, lethargy, and gastrointestinal problems. These side effects were not limited to 
a specific age group, but were also found in across all participants of different ages. Over 
a half of the articles reviewed were experimental studies, while the rest of the articles 
reviewed were observational studies. Almost half of the articles obtained data through 
caregiver reports, medical staff reports, and patient records. Although findings reported 
side effects of AEDs, information regarding how seizure disorders and AEDs affect 
speech and language development in individuals with ID was not available. Majority of 
the articles reviewed focused solely on behavioral side effects and did not address speech 
and language development of these participants.  
SIDE EFFECTS OF AEDS  
Self-injurious behaviors and aggression were a few of the most frequent side 
effects that were reported in the review of 19 articles. Kalachnik et al. (2003), Matson et 
al. (2006), Hanzel et al. (2000), and Gidal et al. (2000) reported self-injurious behaviors 
during AEDs treatment. It appeared that self-injurious behaviors were reported regardless 
of which type of AEDs were used and that individuals with ID had more adverse 
reactions relative to participants without ID.  Kalachnik et al. (2003), Dinkelacker et al. 
(2003), Helmstaedter et al. (2008), Coppola et al. (2008), Beran and Gibson (1998), 
Khurana et al. (1996), and Hurtado et al. (2006) reported aggression in participants 
regardless of type of AED treatment.   
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Other non-behavioral side effects that were frequently reported included 
gastrointestinal problems. Dinkelacker et al. (2003), Bootsma et al. (2004), Gidal et al. 
(2000), Martin et al. (2009), and McKee et al. (2004) reported gastrointestinal problems 
in participants on AED treatment. Bootsma et al. (2004), Mula, Trimble, and Sander 
(2004), Coppola et al. (2008), Beran and Gibson (2008), and Dinkelacker et al. (2003) 
reported psychiatric problems in some participants exposed to AED treatment. Singh and 
White-Scott (2002), Coppola et al. (1998), and Bootsma et al. (2004) reported adverse 
cognitive side effects in participants during AED treatment. These adverse cognitive side 
effects included decrease in concentration and alertness, drowsiness, and cognitive 
slowing. Dinkelacker et al. (2003) also reported memory problems in participants on 
Levetiracetam. Harbord (2002) reported an increase in seizures, rash, headaches, and 
excess weight in participants exposed to AEDs.  Positive side effects of AEDs were also 
reported in addition to the adverse side effects of AEDs. Coffey (2013) reported 
improvement and resolution of self-injuries in an individual with ID and Autism with 
treatment with Phenytoin.  Helmstaedter et al. (2008) reported increase in energy and 
better concentration in participants on Levetiracetam. Hurtado et al. (2006) reported a 
decrease in seizure in participants on Levetiracetam.   
Based on the findings, side effects from AEDs appear to be present in many 
individuals with seizures and ID. However, more research needs to be conducted in order 
to establish more reliable data in distinguishing which symptoms were already present 
before AEDs therapy treatment began. With this information, it may help clinicians 
distinguish which behaviors were already present before therapy in order to be more 
aware in formulating new goals and treatment options. It is also important for practicing 
clinicians to be aware of potential side effects of AEDs so that they can modify 
appropriately in the therapy environment in order to keep clinician and client safe. In 
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addition to modifying the therapy environment to ensure safety for both client and 
clinician, knowing these side effects may help clinicians counsel caregivers on how to 
keep their loved ones safe as well.  
NEWER GENERATION AEDS 
Based on the findings, almost all of the articles, reviewed reported side effects 
from AED therapy such as behavioral or non-behavioral side effect, regardless of the 
brand of medication. It was important to note that multiple studies included participants 
who were taking concomitant medications due to various comorbidities. Since the authors 
did not address effects of concomitant medications, the information regarding these side 
effects was unknown. This information is important for clinicians to be aware of, since 
they are more likely to work with medically fragile populations. Since this review did not 
cover all of the various newer generation AEDs described in a previous sections, 
clinicians do not have the information for possible side effects for other newer generation 
AEDs. 
Based on the results of studies that involved topiramate (TPM) therapy, TPM 
appear to have a variety of side effects. Since the studies reported adverse behaviors, such 
as aggression, this may be important for clinicians to take into consideration during 
therapy treatment. For example, the clinician may incorporate breaks or escapes for the 
client to reduce negative behaviors. Helmstaedter et al. (2008), Dinkelacker et al. (2003), 
Hurtado et al. (2006) reported aggression in participants on Levetiracetam therapy. All of 
the articles that involved Levetiracetam therapy reported aggression as one of the side 
effects in participants. Coppola et al. (2008) and Singh and White-Scott (2002) reported 
behavioral problems and aggression in participants on Topiramate therapy, but also 
reported other non-behavioral side effects such as decreased in alertness and 
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concentration. Martin et al. (2009), Coppola et al. (2008), and Bootsma et al. (2004) 
reported similar side effects in participants on Topiramate therapy, such as mood, mental 
state disorders, and psychotic-like behaviors. Bootsma et al. (2004) and Martin et al. 
(2009) reported gastrointestinal problems in participants on Topiramate therapy. Almost 
all of the studies that involved Topiramate therapy reported adverse cognitive side 
effects, such as cognitive slowing and decrease in alertness and concentration.  
Side effects reported from studies that used Lamotrigine (LTG) therapy were 
variable across studies reviewed. This may negatively impact practicing clinicians in 
preparation for modifying the therapy environment or be prepared incase something 
unexpected occurs, since clinicians may not be aware of all the side effects.  Side effects 
from LTG therapy reported aggression, stereotypy, self-injurious behaviors and 
gastrointestinal problems. Beran and Gibson (1998) and Gidal et al. (2000) reported 
aggressive and self-injurious behaviors in participants on Lamotrigine therapy. Ettinger et 
al. (1998) reported increase in irritability, hyperactivity, and stereotypy in participants on 
Lamotrigine therapy. Gidal et al. (2000) and McKee et al. (2004) reported gastrointestinal 
problems in participants on Lamotrigine therapy. Beran and Gibson (1998) was the only 
study reviewed that reported depression and paranoia in participants on Lamotrigine 
therapy.  
OLDER GENERATION AEDS  
Based on the findings of this review, older generation AEDs were just as likely to 
cause side effects compared to newer generation AEDs. Certain older generation AEDs 
may exacerbate pre-existing problem behaviors that were reported in Kalachnik et al. 
(2003) and Khurana et al. (1996). Khurana et al. (1996) reported increased aggression, 
violence, and irritability in participants on Gabapentin therapy. Kalachnik et al. (2003) 
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reported increased aggressive and self-injurious behaviors in a participant on Clonazepam 
therapy.  This is important for clinicians to be aware that both older and newer generation 
AEDs may potentially cause many adverse effects, which may require clinicians to be 
prepared in working with clients and their family.  
Coffey (2013) was the only study that had resolution with behavioral problems on 
Phenytoin therapy. Matson, Luke, and Mayville (2004) did not report behavioral side 
effects, but did report impaired social skills in participants on Phenytoin therapy.  Hanzel 
et al. (2000) reported self-injurious behaviors, aggressive behaviors, and disruptive 
vocalizations in participants on multiple older generation AEDs (phenobarbital, 
phenytoin, Valproic acid, and Carbamazepine). Matson et al. (2001) also reported self-
injurious behaviors along with disturbed gait, slurred speech, and aggression in 
participants on a variety of older generation AEDs.  
OLDER AND NEWER GENERATION AEDS 
As mentioned in previous sections, it is important for clinicians to be aware of 
different medication interactions; however, more research needs to be conducted to 
further understand AEDs side effects. It clinicians were able to identify specific side 
effects in AEDs, it may help them devise therapy goals, as well as providing appropriate 
counseling for caregivers. Older and newer generation AEDs were evaluated together in 
one of 19 articles reviewed. Harbord (2000) reported significant behavioral side effects in 
participants on a variety of AEDs. In particular, Harbord (2000) reported an increase of 
side effects in individuals with ID while on AEDs regimen. It appeared that participants 
on older or newer AEDs would most likely experience side effects, especially if they are 
taking concomitant AEDs. Harbord (2000) reported similar adverse cognitive side 
effects, such as drowsiness and lethargy as previously mentioned articles that were 
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reported in Singh and White-Scott (2002), Coppola et al. (1998), and Bootsma et al. 
(2004).   
SPEECH AND LANGUAGE DEVELOPMENT 
Based on the findings in the review of 19 articles, a limited number of articles  
addressed speech and language status of participants with ID and seizure disorders. 
Although there was information regarding the behavioral component in this population, 
some studies reported that many participants were non-verbal; a few had some words, 
and relative strength in receptive language. However, based on these findings, there was 
no information provided that included how AEDs side effects affect speech and language 
in individuals with ID and seizure disorders. These participants’ language status was 
lacking additional information. This lack of direct information on speech and language 
would make it difficult for clinicians to incorporate this information into therapy 
straightforwardly. Knowing the side effects of AEDs on speech and language 
development may help clinician distinguish whether if certain treatment goals should be 
continued or discontinued. It may also help clinicians decide if these medication side 
effects interfere in the success of the clients’ speech and language goals.  
One of 19 articles reviewed evaluated the social skills of individuals with ID and 
seizure disorders. Matson, Luke, and Mayville (2004) examined social skills in their 
participants, but did not include the language status or abilities of each participant. 
Although Matson and colleagues measured language and social skills in patients with 
seizures and ID, the results provided were insufficient for practicing clinicians to use in 
their treatment plans. They reported significantly lower scores in the positive non-verbal 
subscale in the MESSIER in participants taking phenytoin, but did not provide further 
information to what this score outcome might mean in terms of speech and language 
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development.   Additional research involving speech and language component and side 
effects of AEDs is critical in developing appropriate treatment goals for this population 
that accommodate the effects of medications for seizures.   
Kalachnik et al. (2003), Ettinger et al. (1998), Coffey (2003), and Hurtado et al. 
(2006) were the few authors who reported language status of participants. Studies that 
reported language status of participant were missing additional information in regards to 
how the language was assessed and where investigators obtained language information. 
The findings show that there was essentially no information regarding how seizure 
medication side effects affect speech and language development in individuals with ID 
and seizures. The lack of speech and language information in regards to seizure 
medication side effects may negatively impact practicing clinicians, since working with 
individuals with ID and seizure disorders is not uncommon in the field of speech therapy.  
CULTURAL AND FAMILY COMPONENT 
Based on the findings, none of the 19 articles included cultural information or 
family dynamics pertaining to the participants. The lack of cultural and family 
information may negatively impact practicing clinician, since clinicians often counsel 
families and caregivers during treatment therapy. As mentioned earlier in previous 
sections, individuals with ID rely heavily on their caregivers in their daily living. Caring 
for individuals with ID or any other medical issues may be considerably stressful for 
families, such as financial burdens. If clinicians have access to resources that involve 
stress levels of caregivers in culturally diverse populations, it may help facilitate 
appropriate counseling support for clients and their families. This would help families 
avoid spending money on therapy that does not accommodate their needs.  Since 
caregivers play a major role in the lives of individuals with ID, it is important to consider 
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cultural and family dynamics when working with these individuals and their families. 
Having knowledge about cultural information is imperative for clinicians, since 
communication disorders are not limited to certain ethnicities. Research is needed in this 
area of interest in order for clinicians to provide support and counseling for clients and 
their families.  
FUTURE RESEARCH 
Future research should examine how AEDs and seizure disorders affect speech 
and language development as well as the ongoing intervention process in individuals with 
ID. Many of the articles reviewed reported side effects of AEDs without information on 
how these effects impact speech and language development. This information is 
important for clinicians to be aware of in order to plan appropriate interventions, since 
many work settings will include individuals with ID and seizure disorders. Other research 
avenues should assess how cultural and family dynamics may affect side effects of AEDs 
in individuals with ID, especially since clinicians work with culturally diverse clients and 
their families. It is also important to examine stress levels of caregivers and how 
treatment affects their family dynamic. Knowing this information may help clinicians 
provide appropriate counseling and support for the clients and their family.  Lastly, it is 
important to examine the side effects of AEDs interactions with other medications, since 
many individuals with ID and seizure disorders were on more than one drug.  
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CONCLUSION 
In this meta-analysis, a total of 19 articles were reviewed to examine the side 
effects of AEDs in individuals with ID and seizure disorders. Behavioral side effects 
from AEDs were found; however, research regarding how AEDs and seizure disorders 
affected speech and language development or therapeutic outcomes was not available. 
Many of the articles reviewed lacked necessary information and data collection and 
analysis varied. Based on the findings, participants on AEDs regimens experienced a 
variety of side effects that included behavioral side effects, adverse cognitive side effects, 
and non-behavioral side effects. Further research is needed in examining AEDs side 
effects on speech and language development, as this may be useful information for 
practicing clinicians who work with these clients.  
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Appendix 
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Goals of Article Participants Data Collection Data Analysis Medication 
Use/Target 
Results Side Effects Critique 
To explore the 
relationship 
between 
barbiturate AEDs 
and antipsychotic 
medication dose. 
 
(Hanzel et al. 
2000)  
 
A total of 7 individuals 
with ID were included in 
this study, 2 dropped due 
to sudden death and 
stroke. All participants 
were diagnosed with ID 
according to the DSM-IV 
criteria. 
Demographic information 
included: age, sex, degree 
of ID, other diagnoses, 
and seizure type. All 
participants used different 
AEDs and antipsychotic 
medication with different 
dosage. 
Index behaviors measured by 
residential living area staffed by 
unit psychologists. Data was 
collected from each participant 
over three time intervals (A, B, 
C) for the analysis of 
challenging behaviors. Index 
behavior rate measures were 
calculated by dividing the 
intervals during which the index 
behavior occurred by the total 
number of intervals. Only 
physical aggression was 
analyzed because this was the 
only index behavior displayed 
by all five individuals. Other 
behaviors were included, but 
some of the data included are 
represented in percentages and 
non-percentages. 
A mean relative 
change score was 
computed for each 
index behavior.  
Period A to C was 
analyzed using 
dependent-groups 
one-tailed t-test. 
An a priori analysis 
was used for period 
A versus period B. 
The Wilcoxon 
matched-pairs 
signed-ranks test 
was used to 
compare period B 
versus period C. 
These medications 
were used for 
physical aggression 
and self-injurious 
behaviors and for 
tonic-clonic and 
complex partial 
seizures.  
Reduction of 
medication to reduce 
behavior rates. 
Phenobarbital, 
Phenytoin, Valproic 
acid, 
Carbamazepine, 
Chlordiazepoxide 
Thioridazine 
Chlorprothixene 
 
All five participants’ seizures were stable across the three measurement 
periods. Physical aggression decreased by 82.3% from period A to B. 93.8% 
from periods A to C and by 19.2 % from periods B to C.  A significant 
reduction in the psychotic medication dose from 146 mg to 98 mg/day to 106 
to 88 mg/day occurred after barbiturate AEDs were discontinued.  
Period A to B: no additional improvement of behavior rates after antipsychotic 
medication reduction with the reduction of antipsychotic medication. 
Period A to B: behavioral rates were not significant. 
Period A to C: decrease in physical aggression after the lowest antipsychotic 
medication dose was reached compared to baseline. 
Combined index behaviors decreased by 81.5% from periods A to B, 96.3% 
from periods A to C and 44.8% periods B to C.   
 
Decrease physical 
aggression. 
Other reported injuries 
include: self-injurious 
behavior, property 
destruction, disruptive 
vocalizations, and verbal 
threats were reported, but 
were not analyzed. 
No information regarding language 
abilities of the participants. No 
inclusion and exclusion criteria 
provided. No cultural information 
about the participants provided. 
No baseline measures were 
mentioned. Authors did not say 
what values are considered 
significant for these parameters. No 
mention if the participants were 
receiving additional services.  
 
The goals of the 
study were to 
observe behavioral 
changes in patients 
receiving 
Levetiracetam 
(LEV) and to 
answer the 
question of 
whether LEV 
exerts a specific 
effect on impulse 
control and 
aggression.  
 
(Helmstaedter et 
al. 2008) 
288 outpatients with 
epilepsy 
Demographic data was 
provided: male gender, 
age, ID, psychiatric 
history, idiopathic, age of 
onset of epilepsy, number 
of AEDs, time of 
introduction of last AED, 
and good responders.  
Control group and LEV 
group  
 
The Barratt Impulsiveness 
Scale-11 
Fragebogens zur Personlichkeit 
be zerebralen Erkrankungen 
Validity of patient 
reports were 
evaluated through 
cross-tabulations of 
patients with proxy 
reports  
Statistics were 
calculated by using 
SSPS 14.0 
Step wise 
regression analysis 
LEV used for seizure 
control 
41% of patients reported good seizure control.  
40% reported good improvement. ID patients responded less well that those for 
whom there was no such information. 37% of patients reported negative side 
effects (12% severe, 25% moderate) 22% of patients noticed positive change 
(7% very positive, 15% moderate)  
41% of patients reported no change. 9% of control group reported any change 
after introduction of the last AED. Patients with ID reported negative side 
effects more often than patients with normal development. Side effects were 
not related to gender, type of epilepsy, dose, time on LEV, number of AEDs 
There were no significant relationship between psychiatric history and 
reporting of behavioral side effects of LEV. 39% of patients reported an 
increase in aggression. 31% reported increase in energy. 25% reported increase 
in concentration/attention. 
Of all 288 patients, 59% reported a behavior change. 
Aggression  
Better concentration 
Increased energy 
 
No inclusion and exclusion criteria 
for each participant. No 
information on ethnicity or cultural 
component. 
Patients with ID were included in 
the study, but information was 
taken from records, no formal 
assessment. No language measures. 
Reported increase/decrease in 
negative and positive behaviors, 
but baseline measures were not 
included. Control group did not 
match experiment group. No 
mention of language for the 
participants with ID or the severity 
of their disability. 
No mention if the participants were 
receiving additional services.  
To assess 
behavioral and 
cognitive effects 
following 
treatment with 
Topiramate in 
children and 
adolescents with 
epilepsy with mild 
to profound ID. 
34 participants (16 males 
and 13 females) enrolled 
in the study 
5 participants dropped out 
within the first 2-weeks of 
TPM therapy  
 
Holmfrid Quality of Life 
Inventory  
Inventory was read by two 
neuropsychologist to caregivers 
Statistical Analysis 
was performed 
with the SPSS 10.0 
program for 
Windows. 
TPM used to control 
both partial and 
generalized epileptic 
seizures in pediatric 
patients. 
Results at 3 months: 
Worsening of total score 20 of 29 patients (69%). Results at 6 months: 
9 of the 29 children dropped out of the study. 7 participants dropped because of 
persistence of seizures and 2 because of adverse side effects (aggressiveness 
and psychotic-like behavior, decreased appetite). For the remaining patients, 9 
patients’ score worsened, and 11 remained unchanged. Results at 12 months: 
2 more patients dropped out because of poor efficacy of seizure frequency. 
Remaining 18 patients: 6 reported worsening scores (6%) and 12 patients’ 
scores were unchanged.   
Worsening of behavior occurred in 19 patients (66%) at 3 months. (Activation 
Aggressiveness 
Psychotic-like behavior  
Decreased in appetite 
Tiredness and drowsiness 
Decrease in concentration 
and alertness  
 
No cultural information regarding 
the participants was included.  
No information if these participants 
were receiving additional services.  
No information about language 
development was provided.  
Reported worsening of behaviors or 
symptoms but did not provide 
baseline measures.  
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(Coppola et al. 
2008) 
and tiredness and drowsiness seemed to be most affected)  
6-12 months follow-up: behaviors scores remained worsened in 65 and 45% of 
cases 
38% decrease in concentration  
24% reported decrease in alertness  
To examine the 
relationship 
between social 
skills of 
individuals with ID 
and AEDs. 
 
(Matson, Luke, 
and Mayville 
2004) 
130 participants (Male 60, 
female 70) from Pinecrest 
developmental center  
Ethnicity of the 
participants were provided 
(Caucasian and African 
American)  
Some of the participants 
had other diagnosis such 
as one or more 
psychological conditions  
Participants were divided 
into two groups and were 
matched on variables of 
age, gender and level of 
ID.  
The Matson Evaluation of 
Social Skills for individuals 
with severe retardation 
(MESSIER) used to measure 
social skills.  
Data was collected from direct-
care workers who worked with 
the participant for a minimum 
of 6 months prior to the study. 
Data was reported on a Likert 
scale. 
ANOVA statistical 
analysis 
Phenytoin 
Carbamazepine 
Valproic Acid  
AEDs used for 
seizure control 
No significant differences were found between carbamazepine group and the 
carbamazepine control group on any of MESSIER subscales.  
No significant differences were found between Valproic acid group and the 
Valproic acid control group on any of MESSIER subscales.  
Significant differences were found between the phenytoin group and the 
phenytoin-control group. Phenytoin group had a significantly lower score on 
the positive non-verbal subscale on the MESSIER. Phenytoin group had a 
significantly lower score on the General Positive subscale than the phenytoin-
control group 
 
No side effects reported.  
 
No inclusion or exclusion criteria. 
No cultural information provided.  
No language assessment was 
conducted. No baseline measures 
reported. Missing information 
regarding language status and level 
of ID  
 
To report the 
emergence of a 
syndrome of 
aggressive 
behavior provoked 
by Lamotrigine 
(LTG) in patients 
with epilepsy and 
intellectual 
challenge.   
 
(Beran and Gibson 
1998) 
19 participants (16 male 
and 3 women; age 17-54 
years).  
Referred from centers that 
specialized in intellectual 
disability and who had 
LTG added to their AED 
regimen  
Demographic data: age, 
sex, and use of LTG, other 
AEDs, assessment of 
patients’ behavior, 
subsequent to any 
behavior changes. 
Patients had poorly 
controlled seizures.  
Information regarding how data 
was collected for each 
participant was not provided, 
However, there is a table that 
provided information: patients, 
dosages, and behavioral 
changes during LTG treatment. 
Data for patients who were 
taking more than 3 AEDs were 
not included. 
No data analysis LTG used as an add-
on AED regimen for 
patients with poorly 
controlled epilepsy. 
5 of 19 patients discontinued LTG due to aggressive behavior (shouting, 
slamming doors, or damaging furniture, demonstrated violent behaviors) 1 of 
19 patients had signs of aggressive behaviors when LTG was discontinued and 
patient was exposed to vigabatrin and later when a trial of tiagabine was 
initiated (unrelated to LTG). In these 5 patients, 2 of 19 patients had LTG 
discontinued due to unacceptable aggressive behavior, but LTG was 
reintroduced consequent of inability to control seizures (and continued to have 
aggressive behaviors) 
Aggressive behaviors in all 5 patients stopped when LTG was discontinued. 
For the 12 patients who continued LTG therapy without interruption: 4 of 12 
had behavior problems other than aggression (paranoia, lethargy, depression, 
withdrawn); 4 patients had no change in behavior; 3 patients showed 
aggression; 1 patients showed behavioral improvement with LTG treatment. 
Aggressive behavior  
Paranoia 
Seemed withdrawn  
Lethargy 
Depression 
No inclusion or exclusion criteria 
reported.  
No cultural information included. 
No language status of participants. 
No information about the level of 
ID for these patients was. Missing 
information  
To describe 
significant positive 
of negative 
psychotrophic 
effects of LTG 
observed in 
epilepsy patients 
with ID.  
 
(Ettinger et al. 
1998) 
7 patients who had ID 
were selected from 20 
patients who had LTG.  
5 of 7 patients had 
Lennox-Gastaut syndrome 
(LGS)  
Demographic information 
was provided: age, sex 
Aberrant Behavioral Checklist 
(ABC): questions are classified 
under categories by “irritability, 
lethargy, stereotypy-abnormal 
repetitive behaviors, 
hyperactivity, and inappropriate 
speech”  
1 residential staff member who 
was familiar with the patient 
and the parents of the 2 patients 
living at home to answer each 
question comparing behaviors 
before the introduction of LTG, 
No data analysis  LTG used in addition 
to other AEDs for 
seizure control. 
Case Reports: Patient 4 had behavioral improvement. Patient 4 became less 
hyperactive, less irritable, demonstrated more compliance with simple 
instructions. Behavioral improvements remain intact during the 6-month 
follow-up. Patient 5 had behavioral deterioration with the increase dosage of 
LTG. Patient 5 became more irritable, displaying temper tantrums, and 
becoming less cooperative, became hyperactive and difficulty with standing or 
sitting in one spot. Developed a new behavior of smearing feces. These 
behaviors were present during the 6-month follow-up. Patient 6 had behavioral 
deterioration. Within 1-month of LTG treatment, increase of LTG dosage, 
behavioral deterioration worsened (irritability, crying, screaming, temper 
tantrums, hyperactive, restlessness and inability to sit still, and stereotypy 
increased). Behavioral problems continued for 9 months with LTG treatment. 
Behavioral problems resolved when LTG was stopped, but with the same VPA 
Increased irritability 
Increased hyperactivity 
Increased stereotypy 
Limited demographic information.  
Missing information: patient 
selection criteria, case reports for 
rest of participants, cultural 
information, level of ID, additional 
services, baseline and outcome 
measures, data analysis, language 
abilities of rest of participants 
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with a time point after 
maintenance LTG dose had 
been achieved.  
Summary of patient data was 
provided in addition to 3 of 7 
brief case reports of some of the 
participants. 
dose. Improvement in behavior continued (up to 3-months follow-up).  Data 
for the rest of the participants from table: Patient 1: decreased irritability, 
lethargy, hyperactivity, and perseveration. Patient 2: decreased in irritability, 
hyperactivity, and increased cooperation.  
Patient 3: decreased in lethargy, and increased in cooperation and social 
engagement. 
Patient 7: increased in irritability. 
To resolve self-
injury with 
phenytoin in a man 
with autism and ID 
 
(Coffey 2013) 
Extensive patient history 
provided 
21-year-old man  
Diagnosed with ID and 
Autism 
Self-injurious behaviors 
Non-verbal; required full-
time home care 
Behavioral intervention 
was reported ineffective 
for this individual  
The data provided was 
anecdotal from a physician  
The information provided was 
based on observation 
No data analysis  Medications used for 
self-injurious 
behaviors due to 
Frontal Lobe 
seizures 
Phenytoin for 
injurious behaviors 
Lorazepam for 
injurious behaviors 
Self-injurious behaviors resolved with phenytoin  
Physician reported that patient returned to the hospital on two occasions, each 
associated with subtherapeutic serum phenytoin levels.  
Self-injurious behaviors: 
biting, hitting, head 
banging were resolved 
with phenytoin  
Missing information: participant 
selection criteria, patient 
characteristics, cultural 
information, data analysis, and 
outcome measures 
To determine the 
usefulness of 
Topiramate in 
individuals with 
intractable mixed 
seizures with ID 
and developmental 
disabilities (DD) 
 
(Singh and White-
Scott 2002) 
Participants selected from 
368 epilepsy patients who 
were older than 21 and 
had ID and DD. 
Study included 20 patients 
(8 females; 12 males).  
Inclusion criteria: mixed 
seizures that were 
uncontrolled by treatment 
with standard or newer 
AEDs, or intolerable 
adverse effects with 
current AED therapy.  
Exclusion criteria: patients 
with history of renal 
stones  
Demographic information 
included  
Information collected through 
caregiver reports and physician 
evaluation.  
The investigator rated 
improvement as worse, none, 
minimal, moderate or marked. 
Patients assessed their own 
improvements, but authors did 
not mention any information 
about the patients’ language 
abilities.  
 
No information 
regarding how the 
data was analyzed. 
Percentages of 
those who had 
seizure reduction 
were provided. 
No method of how 
the data was 
analyzed.   
 
Topiramate was used 
as an add-on AED to 
target seizure control  
Other AEDs that the 
patients used were 
combinations of 
phenytoin, 
carbamazepine, 
phenobarbital, 
primidone, 
lamotrigine, or 
divalproate sodium.   
 
 4 patients discontinued the study  
Seizure frequency was reduced in 11 of 16 patients (69%) 
Two patients were seizure free (13%) 
No change in seizure frequency in three patients  
Seizure duration reduced in 7 patients (44%) 
Global improvement based on investigator, showed improvement was 
moderate in 15 patients, and none to minimal in 3 patients. 
Overall improvement was rated as excellent by 13 patients, fair to good by one 
patient and poor to fair or fair by 4 patients.  
Reductions in baseline AED dosages were achieved in 13 patients  
Improved alertness was evidenced in 11 of 16 patients (69%) 
Emergency room visits for seizures did not increase or increase (Reported, but 
no data to support) 
 
Behavior problem  
Decreased alertness 
Drowsiness 
Increase in seizures 
Abnormal movement (due 
to valproate)  
Disorientation, 
unsteadiness, and 
pneumonia 
Low platelets 
Low White blood cell 
count  
Missing information: what 
assessments were used to classify 
IQ; additional services; who 
classified seizure type; how data 
was analyzed, baseline for global 
improvement, language abilities, 
cultural information, data analysis, 
and definition of significance 
To review the 
AED histories of a 
cohort of children 
with epilepsy to 
determine the 
incidence of SSE 
(significant side 
effects) and other 
factors that may 
have influenced 
the incidence of 
SSE.  
 
(Harbord 2000) 
216 children and 
adolescents (107 girls and 
109 boys, age ranged 3 
months to 18 years). All 
participants were seen by 
the author over a two-year 
period. Consultations 
occurred in 3 settings: 
hospital outpatient clinics, 
hospital in-patients, and 
private practices.  
 
 
 
Parent reports 
Author did not mention how 
data from parent reports were 
recorded.  
No data analysis  AEDs: 
Carbamazepine, 
Clobazam, 
Clonazepam, 
Ethosuximide, 
Lamotrigine, 
Phenobarbitone, 
Phenytoin, Sodium 
Valproate, and 
Vigabatrin were used 
to control seizures.  
SSE occurred in 15% of drug exposures (7% due to behavioral changes: 
irritability, aggression or hyperactivity; 8% were due other factors: rash, 
headache, gastrointestinal disturbance or drowsiness). Behavioral SSEs were 
found most often with Clobazam, Clonazepam, and Phenobarbital (13-17%). 
Behavioral SSEs were found least often with controlled released 
Carbamazepine, Ethosuximide, and Lamotrigine (2-4%). Non-behavioral SSEs 
were most common with regular Carbamazepine, Phenytoin, and 
Phenobarbitone (16-21%) and least often with sodium valproate and Clobazam 
(2-3%). 
57 children (26%) experienced at least on SSE (19 children had SSEs to more 
than one AED; 12 children experienced SSEs with 2 AEDs; 6 children 
experienced SSEs with 3 AEDs; 1 child experienced SSEs with 4 AEDs).   27 
of 67 children (40%) had SSEs compared with 30 (20%) of those with normal 
cognition and development. This was due to difference in behavioral SSE in 
Behavioral SSEs were not 
described. 
Non-behavioral SSE 
include: rash 
Drowsiness 
Hirsutism 
Tremor  
More seizures  
Headaches  
Lethargy 
Excess weight 
 
 
Limited demographic information. 
Missing information: patient 
characteristics, cultural component, 
IQ tests and administration, 
participant selection criteria, data 
collection, behavioral side effects, 
additional services, and seizure 
type 
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children with ID (28%) and only 6% of those with normal cognition. Children 
with ID were exposed to an average of 3 AEDs compared to an average of 1.9 
for typically developing children. (Implied that children with ID had more 
refractory seizures). Comparing incidence: children with ID had one SSE for 
every 5.3 AEDs, compared with 1: 8.6 AEDs for the typically developing 
group.  Behavioral SSE occurred in 1 : 9.6 AEDs for children with ID and 1 : 
31.8 in the typically developing group.  
Non-behavioral SSE incidence were similar: 1 : 11.9 AEDs in children with ID 
and 1 : 11.7 AEDs in typically developing.   
To present the 
authors’ 
experience with 
the efficacy, 
safety, and 
tolerability of 
gabapentin in 
children with 
intractable 
epilepsy.  
 
(Khurana et al. 
1996)  
32 children with refractory 
partial epilepsy who 
received Gabapentin as an 
add-on medication to their 
AED regimen.  
Inclusion and exclusion 
criteria included  
 
 
  
Data was collected through 
monthly evaluations and phone-
interviews with main-caregiver 
of each participant.  
Response to therapy was 
divided into categories. 
Adverse experiences was coded 
on a severity score from 0 
(nonexistent) to 3 (severe 
enough to warrant 
discontinuation, additional 
therapy, or both)  
The Wilcoxon 
Rank Sum Test 
was used to 
determine 
differences 
between baseline 
and gabapentin 
therapy in response 
scores, response 
rate, and in the 
adverse effects 
score.  
Student t test  
The Mann-
Whitney rank sum 
test  
The Fisher Exact 
Test 
The Pearson 
product-moment 
correlations were 
used in data 
analysis.  
Gabapentin used as 
an add-on AED for 
refractory partial 
seizures.  
Efficacy: 11 patients had a greater 50% reduction in seizures frequency. 4 had 
improvement of 25 to 50% seizure frequency. 16 patients had no significant 
responses to the change in seizure frequencies. 2 patients became seizure free 
and 4 patients were almost seizure free. 4 of 11 patients 10 years of age or 
older had more than 50% reduction in frequency of seizures. 7 of 21 children 
younger than 10 years had a more than 50% improvement.  Mean age of the 
group that responded with a better than 50% improvements were 7.4 years and 
the mean age for the group that did not respond was 9.3 years. 7 patients 
discontinued Gabapentin due to lack of efficacy and 1 because of skin rash. 2 
patients discontinued Gabapentin despite of seizure improvements due to 
behavioral problems. 3rd patient discontinued Gabapentin due to lack of 
efficacy and behavioral problems. There were no effects of age or of the 
presence or absence of ID on the number of AEDs before or during gabapentin 
therapy.  17 patients had adverse experience and 15 of 17 had behavioral 
problems. Behavioral problems for 4 patients required physician intervention. 
Of the 4 patients that required physician intervention, 3 reverted back to 
baseline after stopping Gabapentin therapy. 11 children had increased 
impulsiveness, irritability, and hyperactivity. 1 child had a rash, and 1 child 
had facial edema from apparent exacerbation of pre-existing choreoathetosis. 
14 of 15 patients who had experienced behavioral side effects were 10 years or 
younger and 1 patient who had experienced behavioral side effects was over 10 
years of age. Of the 15 patients who had experienced behavioral side effects, 
all of the patients had ID with baseline attention deficit disorder, behavioral 
problems, or both.  7 of 21 patients (10 years old or younger than 10 years of 
age) with ID did not have adverse effects. None of 6 typically developing 
patients and 1 participant with ID (older than 10 years of age) had behavioral 
adverse effects.  
Rash  
Hyperactivity 
Displayed more 
aggressive and violent 
outbursts and mood 
swings  
Increased impulsiveness 
Increased irritability  
Facial edema  
Exacerbation of pre-
existing choreoathetosis  
Limited participant demographics.  
Missing information: cultural 
information, level of ID, language 
abilities, baseline and outcome 
measures, additional services, 
Vague coding scale 
To evaluate the 
efficacy of LTG in 
developmentally 
disabled persons 
with epilepsy.  
 
(Gidal et al. 2000)  
25 men and 19 women 
with the age range of 8 to 
59 years. Medical and 
pharmacy records were 
review to identify all 
patients who had or were 
receiving LTG. 
 
  
Phase 1: baseline period of 2-
months before initiation of 
LTG. Phase 2: designated as the 
drug-escalated period (3 
months). Phase 3: treatment 
observation period). Adverse 
effect data was collected from 
nursing and medical progress 
notes.  
Percentage of 
change in 
frequency were 
calculated: 
(treatment period 
average-baseline 
average)/ baseline 
average X 100 
Student t test was 
used to compare 
phase 1 and phase 
3 for paired data.  
Statistical 
significance was 
LTG used for 
intractable seizure 
disorders in patients 
with ID and epilepsy.  
Patients were taking 
other AEDs: 
carbamazepine, 
phenytoin, 
phenobarbital, 
primidone, valproic 
acid, gabapentin, and 
felbamate 
Seizure frequency reduction greater than 75% was seen in 32% (n=14) of 
patients 
 
23% of patients (n=10) had a 50-74% reduction in seizure frequency.  11% of 
patients (n=5) experienced 25-49% reduction in seizure frequency. 14% of 
patients (n=6) had between 0 and 24% reduction in seizure frequency. 21% of 
patients had an increase of seizure frequencies. 
 Significant reductions of 48% were noted in the frequency of generalized 
tonic-clonic seizures. No significance in partial seizure reductions, or in mixed-
typed seizures. 6 patients were seizure free during treatment evaluation period. 
No episode of status epilepticus occurred.  
Reported adverse drug effects: gastrointestinal symptoms (vomiting) noted in 
two patients; 5 of 44 patients displayed self-injurious behaviors at baseline and 
after treatment these behaviors increased.  
Self-injurious behaviors  
Gastrointestinal symptoms  
Limited demographic data 
Missing information: cultural 
component, language status, 
additional services 
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assigned P<0.05 Treatment was discontinued for 11% of patients due to adverse effects.  
To provide 
descriptive 
characteristics of 
individuals with ID 
and seizure 
disorders.  
 
(Matson, Mayville, 
Bamburg, and 
Eckholdt 2001)  
248 participants diagnosed 
with ID based on DSM-IV 
criteria. Level of ID 
included.  
Demographic data 
provided.  
Participants were divided 
into one control group and 
one experimental group  
Collected data through the 
Matson Evaluation of Drug 
Side effects (MEDS)  
Clinical psychologists were 
trained to administer the 
MEDS. Likert scale 
Measures that required for 
physiological and lab findings 
were obtained their patient 
records.  
ANOVA- 
significant level is 
P<0.01 
Descriptive 
analysis  
AEDs for seizure 
control  
Phenobarbital 
Divalproex 
Carbamazepine  
Phenytoin 
Gabapentin 
Primidone 
 
 
  
 No significant main interactions were found between the different AEDs. 
When type of AED was used for the independent variable and MEDS score 
was used as the dependent variable, no significance was found.  
Descriptive analysis: most endorsed items were abnormal white blood cell 
count, disturbed gait, balance disorders, self-injurious behaviors, and 
aggression or destructiveness 
Other measures using ANOVA were not significant. However significant 
differences were found in the severity of subscales for endocrine/genitourinary 
and CNS–general. 
Type of medication taken by participants for items in which a between-group 
significance was found.    
Abnormal white blood cell 
count 
Disturbed gait  
Balance disorders  
Self-injurious behaviors 
Aggression or 
destructiveness 
Slurred speech  
Toothache 
Menstrual changes  
Missing information: participant 
selection criteria, cultural 
information, additional services, 
seizure type, treatment of other 
comorbidities 
Share authors’ 
clinical experience 
with treatment-
emergent adverse 
effects of 
Levetiracetam 
(LEV) 
 
(Dinkelacker et al. 
2003)   
33 patients with a long 
history of refractory 
epilepsy were included. 
Computer-based library of 
medical records were 
used.  
Inclusion and exclusion 
criteria provided. 
Demographic information 
provided  
Patient characteristics 
included 
 
Efficacy and aggressive 
symptoms were derived from 
patients’ record, including MRI 
scans 1-3 prior to aggressive 
episodes.  
 
 
No data analysis  LEV used as an add-
on therapy for 
refractory epilepsy  
Group 1: 14 patients experienced irritability that did not require change in 
AEDs. These symptoms were rated as mild. 5 of 14 patients had learning 
disabilities. 
Group 2: 10 patients had moderate irritability that required change in 
medication. 1 patient had pronounced and 2 patients had moderate learning 
disabilities.   
Group 3: 9 patients showed overt physical aggression. Patients in -group 3 had 
some history of aggression. 7 of 9 individuals threaten others or exerted 
physical aggression. 2 of 9 patients required psychiatric emergency services. 
Highest percentage of learning disabilities was found in the group with severe 
aggressive symptoms.   
Increased aggression  
Increased irritability 
Fatigue  
Sleep disorders 
Memory problems  
Gastrointestinal adverse 
effects 
Depression  
Missing information: cultural 
component, level of ID, baseline 
and outcome measures, language 
status, data analysis, additional 
services, how were adverse effects 
defined/recorded 
Performed a 
systematic audit of 
Topiramate (TPM) 
use in “real-life” 
setting of our 
center, analyzing 
all patients who 
had received or 
who is still using 
TPM.  
 
(Bootsma et al. 
2004)  
470 patients were 
identified through a 
medical information 
system (166 patients had 
ID) Demographic 
information and patient 
characteristics were 
provided.  
Epilepsy and seizure were 
classified under the ILAE. 
Gender was equally 
distributed 
Mean age of study was 
34.9  
Data collected through patient 
records. Treating neurologists 
were asked additional 
information incase of any 
uncertainty.  
Kaplan-Meier 
analysis for 
retention rates 
SPSS 10.0 analysis 
Mann-Whitney U 
test and Pearson 
coefficient for 
ordinal data  
  
TPM used for 
refractory epilepsy  
TPM titration schedules were provided. Most frequent applied strategy was not 
a fixed scheduled, but varies due to patient response and seizure frequency. 
Most frequent side effects were mental slowing, and language problems at 6, 
12, and 18 months. Weight loss was reported in early stages of treatment. 
Mood problems (agitation) reported at 18 months and urogenital problems at 
24 months of follow-up. At 6 months, 49% reported side effects. At 12 months 
47% reported side effects. At 18 months, 48.4% reported side effects. At 34 
months, 38.2% reported side effects. 269 of 470 patients discontinued at some 
point TPM: 27% quit due to adverse effects; 17.2% quit due to lack of 
efficacy; 14% quit due to a combination of reasons. The most common reason 
for discontinuing TPM was due to cognitive slowing (27%), dysphasia (16%), 
and mood disorders (hyperirritability, agitation, aggression) (11.9%). 
Gastrointestinal complaints occurred in 10.1% of patients.  
Weight loss 
Mood problems  
Gastrointestinal problems 
Dysphasia 
Cognitive slowing 
Missing information: cultural 
component, Level of ID, language 
abilities, definition of significance, 
additional services, participant 
selection criteria 
To investigate the 
prevalence and 
psychopathological 
features of 
psychiatric adverse 
events (PAEs) in 
patients with 
learning 
disabilities (LD) 
with LEV therapy. 
 
118 (64 males and 54 
females) of 517 patients 
with epilepsy were 
identified with LD. 
Demographic data and 
distribution of variables 
associated with PAEs was 
provided.  
Epilepsy and seizure 
diagnoses were based on 
ILAE classification.  
Data was obtained through 
evaluating patients at each visit. 
Fisher’s exact test 
and Pearson 
coefficient  
ANOVA 
LEV used to treat 
epilepsy in patients 
with LD.  
15 patients experience PAEs during LEV therapy.  
2 developed an affective disorder; 2 developed emotional liability; 9 developed 
aggressive behavior; and 2 had personality changes such as agitation, anger 
and hostile behavior. 
10 discontinued LEV due to PAEs; 3 received dose reduction and 2 remained 
on the same dose.  
Psychotropic drug prescription was required in three patients while 1 patient 
was admitted to the hospital because of PAEs. 
Did not find specific seizure pattern associated to PAEs onset.  
3 patients were seizure free during PAEs, one was seizure free but behavior 
deteriorated after a cluster of seizures, five experienced no change in seizure 
PAEs  
Agitation 
Anger  
Hostile behavior 
 
Missing information: 
Patient selection criteria, cultural 
information, who conducted IQ 
testing, language assessment, data 
collection, additional services, and 
caregiver role 
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(Mula, Trimble, 
and Sander 2004)   
frequency, five had seizure reduction, and only one patient experienced seizure 
worsening.  
Significant association between patients with and without PAEs with 
psychiatric history and a previous history of status epilepticus.  
 To evaluate 
whether treatment 
with LEV 
adversely impacts 
behavior in people 
with ID and/or 
acquired brain 
damage.  
 
(Hurtado et al. 
2006)  
35 individual with 
refractory epilepsy were 
observed over 3 years. 
Demographic and patient 
characteristics were 
provided (Cognitive 
status; LEV status; No. of 
seizure types; seizure 
change on LEV, 
convulsive seizures on 
LEV, RBS, challenging 
frequency, behavior 
difficulty, scale challenge, 
no. of other AEDs, and 
taking neuroleptics). 
Language competence was 
derived from neurological 
reports.  
  
Ritualistic behavior rating scale 
(RBS)  
Challenging Behavior scale 
(CBS)  
Details relating to history of 
challenging behavior, side 
effects from previous AEDs, 
etc. were obtained from medical 
files   
Behavior measures were 
recorded in two separate 8-
week intervals: once when on 
LEV and once off LEV. Seizure 
diaries were kept my care staff 
Wilcoxon analysis  
Mann-Whitney U 
test  
Spearman P 
Pearson r  
P>0.05 was 
considered 
significant 
LEV used as an add-
on AED for 
refractory epilepsy.  
Frequency and severity of ritualistic behaviors were rated higher on RBS scale. 
Only 5 patients obtained better ratings while on LEV. CBS scale: patients 
taking LEV were more likely to have problem behaviors. Frequency of 
challenging behavior and level of severity were significantly higher in patients 
on LEV. Challenge scores were significantly higher in patients on LE. 20 
patients received higher rating on the computed challenged measure when on 
LEV; 14 obtained a score at least 50% higher. Only 6 patients obtained a lower 
rating (behavior improved).  
Verbal aggression was rated as significantly more challenging and shouting as 
more frequent and challenging when patients were on LEV. Patients had 
significantly fewer seizures on LEV. 17 of 28 patients with seizures 
experienced reduction in seizures. No significant differences were found 
between seizure type and seizure frequency. Did not find significant 
correlation between seizure reduction and behavioral worsening for patients.  
 
Report did not include 
specific behaviors  
Limited demographic information.  
Missing information: patient 
selection criteria, language 
assessment, level of ID, additional 
services, challenging behavior data, 
baseline and outcome measures 
To examine the 
effectiveness and 
behavioral 
outcomes of 
patients with ID 
treated with TPM 
for epilepsy.  
 
(Martin et al. 
2009)  
29 patients with Cerebral 
Palsy were identified from 
Epilepsy Centre Kork 
(Seguin Clinic for Persons 
with Severe ID). 
Inclusion: patients with 
epilepsy (less that 4 years 
old) with any type of 
seizures and ID that had 
unsatisfactory results with 
previous AEDs and TPM 
were considered.  
Social skills behavior data was 
collected through MESSIER 
and behavioral disturbance 
through ABC 
WHO Adverse Reaction 
Terminology was used to code 
adverse events  
Monthly seizure rates were 
calculated 
Responder rates were based on 
caregivers’ diaries. 
Baseline measures were 
provided to see changes over 
the course of the study.   
No formal data 
analysis because 
data was 
observational in 
nature. 
Wilcoxon’s 
asymptotic test and 
modified ITT (m-
ITT) were used as 
an exploratory 
measure   
 
 
TPM used to treat 
epilepsy in patients 
with ID.  
Slight improvement in all subscales of the ABC except for hyperactivity. 
Evaluation from the MESSIER revealed some improvement in all subscales for 
both groups with an exception of minimal deterioration on scale M6. Seizure 
frequencies decreased from m-ITT group during TPM treatment (V2-V5). 
8 patients (38.1%) experience increase in seizure frequency and 13 patients 
(61.9%) experienced a seizure reduction. 7 patients had at least 50% reduction 
in seizures; 3 patients had a reduction of at least 75% of seizures, and 1 patient 
experienced complete seizure freedom. 57 treatment-emergent adverse events 
(TEAEs) were reported in 21 of 29 patients (72.4%). 23 of these (40.4%) were 
at least possibly related to TPM treatment. 5 serious TEAEs occurred in 4 
patients (fracture tibia head, abscess in left popliteal fossa with recurrent 
edema, and rheumatic fever.) 
Two deaths occurred; Sudden unexpected death in epilepsy was assumed, but 
no autopsy was performed. Serious TEAEs were judged to not be causal due to 
TPM treatment. Physicians rated tolerability as “very good” or “good” in 
82.8% of 24 patients. Cognitive tolerability was rated as “very good” or 
“good” in 79.3% of 24 patients.  
Gastrointestinal disorders 
Nervousness/restlessness 
Tiredness/sedation 
Ear/nose/throat infections, 
injuries 
Mental state disorders 
 
Limited demographic information.  
Missing information: language 
abilities, cultural information, 
patient selection exclusion criteria, 
where IQ information obtained, 
additional services 
To examine the 
effects of 
adjunctive LTG 
therapy on seizure 
reduction, safety 
and tolerability, 
and behaviors in 
adolescents with 
ID through a sub-
analysis.  
22 patients (age range 14 
to 20 years) were 
included.  
Inclusion criteria: patients 
(12 to 20 years old) who 
had a diagnosis of 
epilepsy classified by the 
ILAE; diagnosis of ID 
based on the DSM-IV 
Revised criteria; body 
Seizure counts were obtained 
through caregiver reports 
(investigator coded and 
reviewed at predetermined 
intervals)  
Investigator assessment of 
clinical status (rated as mild, 
moderate, or marked 
deterioration or change, or mild, 
moderate, or marked 
Focused on 
percentage 
reduction of 
patients’ seizure 
frequency. 
All data 
summarized by 
using descriptive 
statistics.  
t-tests were used to 
LTG therapy for 
refractory epilepsy in 
adolescents with ID.  
During maintenance interval: 25% of patients were seizure free; 45% of 
patients had 75% reduction in seizure, and 60% of patients had 50% in 
reduction of seizures. During optimization phase, 15% of patients were seizure 
free, 45% of patients had a 50% reduction in seizures, and 40% of patients had 
a 75% reduction in seizures. HIS mean score was significantly improved. 
Group mean scores showed better adaptive functioning compared with 
baseline. ABC scores revealed the participants had significant improvement. 
Statistically significant improvements were noted in the areas of lethargy, 
hyperactivity, and stereotypy. Investigator concluded that overall clinical status 
for completers was improved. 80% of patients had no change in adverse events 
Vomiting  
Dizziness 
Somnolence 
Abdominal pain  
Missing information: cultural 
information, language status, 
additional services 
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(McKee et al. 
2004)  
weight of 25kg or more; 
receiving 3 AEDs at 
enrollment; and 
experienced at least two 
seizures per month during 
the 3 months prior to 
enrollment and during 
each of two baseline 
periods of 4 weeks in 
duration.  
 
Exclusion criteria: if 
patients had used of any 
investigational drug within 
4 weeks of initiation of the 
study, had a vagal nerve 
stimulator place, or had 
been previously exposed 
to LTG.  
Demographics (age, sex, 
race) and patient 
characteristics (severity of 
ID; seizure etiology; most 
common AEDs used, etc.) 
were provided.  
improvement) 
ABC scores obtained during 
assessments conducted during 
screening phase and at the 
baseline, escalation, 
maintenance, and optimization 
phases.   
Habilitative Improvement Scale 
(HIS) scores completed by 
caregivers. 
Adverse events were defined 
and were recorded by 
caregivers. Investigator at the 
clinic reviewed and compiled 
the data.  
 
 
examine changes 
from baseline on 
the ABC scores 
and HIS scores 
during the 
maintenance and 
optimization 
phases.  
All efficacy data 
reporting was 
based on data 
summaries for 
completers only (n 
= 20).  
All demographic 
and safety 
reporting was 
based on data 
summaries for 
patients entering 
the escalation 
period and taking 
at least one dose of 
LTG (n = 22). 
at the end of the study. 15% of patients had some improvement in adverse 
events from baseline to the end of the maintenance phase (with addition of 
LTG dosage). 
Social function improved in 50% of patients.14% of patients experienced 
vomiting during the optimization phase. No other drug-related was reported in 
more than 10% of patients in the group. Dizziness, somnolence, and abdominal 
pain were infrequently reported (n =2; 9%)  
 
To describe an 
individual with ID 
who displayed 
behavioral 
exacerbation 
associated with the 
use of clonazepam, 
which was 
prescribed to treat 
problem behaviors. 
 
(Kalachnik, 
Hanzel, Sevenich, 
and Harder 2003)  
49-year-old male with 
severe ID and had tonic-
clonic seizures resulting 
from asphyxia during 
birth. 
Single-case study: all 
information and data were 
collected through patient’s 
medical records and 
behavioral records.   
Receptive language skills 
were reported as good.  
Participant continued to 
receive non-
psychopharmacological 
interventions  
 
Tantrum behavior was 
measured in the residential 
setting in 15-minute partial 
interval recording.   
Rate of tantrum behavior for 
each drug and dose condition 
was computed by dividing the 
number of intervals in which 
tantrum behavior occurred by 
the total number of intervals 
during the drug and dose 
condition.  
If more than one type of 
tantrum behavior was recorded 
for an interval, the interval was 
counted only once. 
Observational data included.  
Error bars were 
based on 95% 
confidence bands 
derived from z-
approximation to 
the normal 
distribution for 
proportional data.  
Clonazepam therapy 
used to treat 
challenging behavior 
in an individual with 
ID and seizure 
disorder.  
Condition 1 and 2: Clonazepam was prescribed at 2 mg/day, 8.6 and 9.3 
tantrums occurred per week. Conditions 3 to 5:  Clonazepam was reduced and 
5.6, 6.3, and 6.1 tantrums occurred per week, respectively. Condition 6 to 8: 
Clonazepam was discontinued, tantrums decreased to 1.5, 0.2, and 0.2 per 
week, respectively. Statistically significant percentage changes of total 
intervals containing tantrums were detected at 0.05 level of significance.  
Exacerbated tantrum 
behaviors: 
Aggression to other people 
(hitting, kicking, head 
butting)  
Aggression towards 
property  
Self-injurious behaviors  
Limited demographic information 
Missing information: cultural 
component, language assessment, 
procedural, baseline measures, 
seizure frequency, definition of 
significance 
 
  
 61 
References 
Andrews, L.W. (Ed). Anticonvulsants. (2010). Encyclopedia of Depression (Vol. 1, pp. 
28-30). Santa Barbara, CA: Greenwood Press. 
Asato, M. R., Manjunath, R., Sheth, R. D., Phelps, S. J., Wheless, J. W., Hovinga, C. A., . 
. . Zingaro, W. M. (2009). Adolescent and caregiver experiences with epilepsy. J 
Child Neurol, 24(5), 562-571.  
Austin J.K., Huberty TJ, Huster G.A., Dunn D.W. (1999) Does academic achievement in 
children with epilepsy change over time? Dev Med Child Neurol 41, 473–479. 
Beran, R. G., & Gibson, R. J. (1998). Aggressive behaviour in intellectually challenged 
patients with epilepsy treated with lamotrigine. Epilepsia, 39(3), 280-282.  
Bishop, M., & Boag, E. M. (2006). Teachers’ knowledge about epilepsy and attitudes 
toward students with epilepsy: Results of a national survey. Epilepsy & Behavior, 
8(2), 397-405.  
Bootsma, H. P., Coolen, F., Aldenkamp, A. P., Arends, J., Diepman, L., Hulsman, J., 
Lambrecht, L., Leenen, M., Majoie, M., Schellekens, A., & de Krom, M. (2004). 
Topiramate in clinical practice: Long-term experience in patients with refractory 
epilepsy referred to a tertiary epilepsy center. Epilepsy Behavior, 5(3), 380-387.  
Coffey, M. J. (2013). Resolution of self-injury with phenytoin in a man with autism and 
intellectual disability: The role of frontal lobe seizures and catatonia. J ECT, 
29(1), 12-13.  
Coppola, G., Verrotti, A., Resicato, G., Ferrarelli, S., Auricchio, G., Operto, F. F., & 
Pascotto, A. (2008). Topiramate in children and adolescents with epilepsy and 
mental retardation: A prospective study on behavior and cognitive effects. 
Epilepsy Behavior, 12(2), 253-256.  
Corbett J. (1993) Epilepsy and mental handicap. In: A Textbook of Epilepsy, 3rd edn 
(eds J. Laidlaw, A. Richens & J. Oxley), pp. 631–.6 Churchill Livingstone, 
Edinburgh. 
Dinkelacker, V., Dietl, T., Widman, G., Lengler, U., & Elger, C. E. (2003). Aggressive 
behavior of epilepsy patients in the course of levetiracetam add-on therapy: 
Report of 33 mild to severe cases. Epilepsy & Behavior, 4(5), 537-547.  
Epilepsy. (2012). In S. J. Judd (Ed.), Health Reference Series. Learning Disabilities 
Sourcebook (4th ed., pp. 225-232). Detroit: Omnigraphics 
Ettinger, A. B., Weisbrot, D. M., Saracco, J., Dhoon, A., Kanner, A., & Devinsky, Y. 
(1998). Positive and negative psychotropic effects of lamotrigine in patients with 
epilepsy and mental retardation. Epilepsia, 39(8), 874-877.  
 62 
Ferro, M. A., Landgraf, J. M., & Speechley, K. N. (2013). Factor structure of the child 
health questionnaire parent form-50 and predictors of health-related quality of life 
in children with epilepsy. Qual Life Res, 22(8), 2201-2211.  
Gabitril, tiagabine [product information]; 2010. Aspenpharma 
Gidal, B. E., Walker, J. K., Lott, R. S., Shaw, R., Speth, J., Marty, K. J., & Rutecki, P. 
(2000). Efficacy of lamotrigine in institutionalized developmentally disabled 
patients with epilepsy: A retrospective evaluation. Seizure, 9(2), 131-136.  
Guberman A.H., Besag F.M., Brodie M.J., et al. (1999). Lamotrigine-associated rash: 
risk/ benefit considerations in adults and children. Epilepsia, 40(7), 985–91. 
Haggerty, M. (2002). Seizure Disorder. In D. S. Blanchfield & J. L. Longe (Eds.), The 
Gale Encyclopedia of Medicine (2nd ed., Vol. 4, pp. 2984-2990). Detroit: Gale. 
Hanzel, T. E., Bauernfeind, J. D., Kalachnik, J. E., & Harder, S. R. (2000). Results of 
barbiturate antiepileptic drug discontinuation on antipsychotic medication dose in 
individuals with intellectual disability. Journal of Intellectual Disability Research, 
44(2), 155-163.  
Harbord, M. G. (2000). Significant anticonvulsant side effects in children and 
adolescents. Journal of Clinical Neuroscience, 7(3), 213-216.  
Helmstaedter, C., Fritz, N. E., Kockelmann, E., Kosanetzky, N., & Elger, C. E. (2008). 
Positive and negative psychotropic effects of levetiracetam. Epilepsy Behavior, 
13(3), 535-541.  
Hoare, P. (1993). The quality of life of children with chronic epilepsy and their families. 
Seizure, 2(4), 269-275.  
Hung, O. L., & Shih, R. D. (2011). Antiepileptic drugs: the old and the new. Emerg Med 
Clin North Am, 29(1), 141-150.  
Hurtado, B., Koepp, M. J., Sander, J. W., & Thompson, P. J. (2006). The impact of 
levetiracetam on challenging behavior. Epilepsy Behavior, 8(3), 588-592.  
Kalachnik, J.E., Hanzel, T.E., Sevenich, R., & Harder, S.R. (2003). Brief report: 
clonazepam behavioral side effects with an individual with mental retardation. 
Journal of Autism and Developmental Disorders, 33(3), 349-354. 
Keppra, levetiracetam [product information]. Keppra UCB Pharma, Smyrna (GA), 2010. 
Kerr M. (1996) Epilepsy in people with learning disability. Aspects of Epilepsy, 3,1 –6.  
Khurana, D.S., Riviello, J., Helmers, S., Holmes, G., Anderson, J., & Mikati, M. (1996). 
Efficacy of gabapentin therapy in children with refractory partial seizures. Journal 
of pediatrics, 128(6), 829-833. 
Letcher, M. G. (2005). Epilepsy. In B. Narins (Ed.), The Gale Encyclopedia of Genetic 
Disorders (2nd ed., Vol. 1, pp. 422-425). Detroit: Gale. 
 63 
Living with Epilepsy. (2010). In J. B. Shannon (Ed.), Health Reference Series. Brain 
Disorders Sourcebook (3rd ed., pp. 541-546). Detroit: Omnigraphics. 
Martin, P., Schreiner, A., Rettig, K., & Schauble, B. (2009). Topiramate in patients with 
epilepsy and intellectual disability. Epilepsy Behavior, 14(3), 496-502.  
Matson, J. L., Luke, M. A., & Mayville, S. B. (2004). The effects of antiepileptic 
medications on the social skills of individuals with mental retardation. Res Dev 
Disabil, 25(2), 219-228.  
Matson, J.L, Mayville, E.A, & Bamburg, J.W. (2001). An analysis of side effect profiles 
of anti-seizure medications in persons with intellectual disability using the matson 
evaluation of drugs side effects. Journal of intellectual and developmental 
disability, 26(4), 283-295.  
McGrother, C. W., Bhaumik, S., Thorp, C. F., Hauck, A., Branford, D., & Watson, J. M. 
(2006). Epilepsy in adults with intellectual disabilities: Prevalence, associations 
and service implications. Seizure, 15(6), 376-386.  
McKee, J.R., Sunder, T.R, Vuong, A., & Hammer, A.E. (2004). Adjunctive lamotrigine 
for refractory epilepsy in adolescents with mental retardation. Journal of child 
neurology, 21(5), 372-379. 
Motamedi, G., & Meador, K. (2003). Epilepsy and cognition. Epilepsy & Behavior, 4, 
25-38.  
Mula, M., Trimble, M. R., & Sander, J. W. A. S. (2004). Psychiatric adverse events in 
patients with epilepsy and learning disabilities taking levetiracetam. Seizure, 
13(1), 55-57.  
O'Dell, C., Wheless, J. W., & Cloyd, J. (2007). The personal and financial impact of 
repetitive or prolonged seizures on the patient and family. J Child Neurol, 22(5 
Suppl), 61S-70S.  
Pedley, T. A., & Engel, J. (1998). Epilepsy: a comprehensive textbook. Philadelphia: 
Lippincott-Raven. 
Richarson, S.A., et al. (1979). Some characteristics of a population of mentally retarded 
young adults in a british city: A basis for estimating some service needs. Journal 
of Intellectual Disability Research, 23(4), 275-285. 
Singh, B. K., & White-Scott, S. (2002). Role of topiramate in adults with intractable 
epilepsy, mental retardation, and developmental disabilities. Seizure, 11(1), 47-
50.  
Treating Epilepsy. (2010). In J. B. Shannon (Ed.), Health Reference Series. Brain 
Disorders Sourcebook (3rd ed., pp. 527-540). Detroit: Omnigraphics. 
Webster, N. J. (2008). Epilepsy. In Y. Zhang (Ed.), Encyclopedia of Global Health (Vol. 
2, pp. 617-618). Thousand Oaks, CA: SAGE Publications. 
 64 
What Is Epilepsy? (2010). In J. B. Shannon (Ed.), Health Reference Series. Brain 
Disorders Sourcebook (3rd ed., pp. 519-525). Detroit: Omnigraphics.  
Wilfong, A. A. (2002). Treatment considerations: role of vagus nerve stimulator. 
Epilepsy & Behavior, 3(6, Supplement 1), 41-44.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
